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Abstract: 
 
 
COMBINED ASSESSMENT OF DISSOLUTION AND INTESTINAL PERMEABILITY OF 
SOLID ORAL DOSAGE FORMS 
 
 
Assessing dissolution and Caco-2 permeability to estimate the in vivo 
performance of solid oral dosage forms is done since decades. However, permeability 
assays applying Caco-2 monolayers exhibit the drawback that, in contrast to dissolution 
testing, a complete dosage form is not eligible for conventional epithelial permeability 
assays. Hence, an apparatus was developed providing the possibility to assess 
permeability of solid oral dosage forms based on combination of a Caco-2 monolayer 
and a flow through dissolution cell. Combination of the dissolution and permeation 
module was performed using a depressurized stream splitter. Experiments with varying 
propranolol HCl tablets yielded plausible and conclusive results. Furthermore, data of 
these experiments were used to perform computational modelling of the concentration 
time trends within the apparatus. In order to increase throughput and to decrease 
manpower, the apparatus was automated by means of sequential injection technique 
(SIA) permitting online sampling and drug quantification. Finally, experiments with 
furosemide, a BCS class 4 compound, were carried out. 
In summary, a novel tool for has been developed, which is able to monitor 
influences of excipients concomitantly on both dissolution and permeability through the 
small intestinal cell line Caco-2. 
 
Kurzzusammenfassung: 
 
 
KOMBINIERTE BESTIMMUNG VON AUFLÖSUNG UND EPITHELIALER 
PERMEABILITÄT VON FESTEN ORALEN ARZNEIFORMEN 
 
 
Dissolutions- und Permeabilitäts- Tests werden seit längerem zur Abschätzung 
der Bioverfügbarkeit nach oraler Administration verwendet. Traditionelle, auf Caco-2 
Zellmonolayern basierende Permeabilitätstest haben jedoch den Nachteil, daß man - im 
Gegensatz zu Dissolutionstests - nicht die komplette Arzneiform auf ihre epitheliale 
Permeabilität testen kann. Ausgehend davon wurde eine Testapparatur zur 
Permeabilitätsbestimmung fester oraler Arzneiformen entwickelt. Die Kombination 
Permeation- Dissolution wurde hierbei durch eine Verbindung der Module mit Hilfe 
eines druckfreien Stromteilers bewerkstelligt. Experimente mit verschiedenen 
Propranolol HCl Tabletten ergaben plausible und schlüssige Ergebnisse. Des weiteren 
wurden mit Hilfe der Daten aus diesen Experimenten die Konzentrations-Zeit Profile 
innerhalb der Testapparatur mittels eines computerbasierten Modells zu simuliert. Im 
Rahmen der Weiterentwicklung wurde die komplette Testapparatur automatisiert, so 
daß sowohl die Probennahme als auch die Arzneistoffquantifizierung programmiert 
ablaufen. Daneben wurden auch Experimente mit Lasix® Tabletten (40 mg Furosemid) 
durchgeführt. 
Zusammenfassend kann die Testapparatur als neuartiges Werkzeug gesehen 
werden, welches die Sichtbarmachung der Einflüsse von Hilfsstoffen sowohl auf die 
Dissolution als auch auf die intestinale Permeation ermöglicht. 
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1 Introduction 
 
 
Chapter 1 is forming a rationale for developing an apparatus for epithelial 
permeability assessment of solid oral dosage forms. Furthermore, it comprises a 
review of current literature of this particular area of research and reflects the state of 
the art. In view of the needs, the aim of the study is defined and parameters of the 
apparatus to be developed have been defined. 
 
 
 
 
 
 
 
 
 
 
 
Parts of this section have been published in  
 
Motz SA, Bur M, Schäfer UF, Lehr CM. Instrumented approaches to assess epithelia permeability of 
drugs from pharmaceutical formulations, Springer, Ed. Kim KJ, Ehrhardt C, 2007, Book title: “Preclinical 
Biopharmaceutics – In situ, in vitro, and in silico tools for drug absorption studies”.[1]. 
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For most drugs, oral administration of pure active pharmaceutical ingredient 
(API) to patients is not feasible mainly due to low dose/mass and low compliance. To 
circumvent these issues, drugs are formulated in order to provide good compliance 
and better technical solutions for administration. Additionally, for various routes of 
administration, the dosage form may play a key role determining in vivo bioavailability. 
However, only few is known about interaction of cell culture based in vitro methods with 
formulated drugs. 
 
1.1 Rationale for connecting permeation and dissolution measurement 
 
Dissolution and subsequent permeation through intestinal epithelia are 
processes in oral drug absorption whereby each of those may be rate limiting. 
Unnumbered parameters affect both processes, such as ample wetting, appropriate 
swelling and disintegration of the dosage form, dissolution of the active compound 
within intestinal transit time depending on the surrounding microclimate pH, osmolarity, 
and surface tension. While sufficient disintegration and dissolution is a prerequisite for 
oral absorption, critical parameters can be seen in the pH in the GI-lumen and the cell 
covering, more acidic mucus, apical concentration and affinity to active cellular uptake 
or efflux systems, sink condition in the trans-mucosal receptor fluid, concomitant 
administration of meal and disposability of active excipients, just to mention the most 
important. Summarized as L and A of the LADME model, these both processes are the 
only being easily accessible for manipulation by researchers.  
For dissolution testing, many successful efforts have been made to imitate more 
and more closely the physiological surrounding in the GI lumen. Variables such as 
temperature, osmolarity, pH, surface tension, presence of bile salts were altered and 
two in vitro dissolution buffers coming most closely to in vivo conditions were reported 
as FaSSIF (fasted state simulated intestinal fluid) and FeSSIF (fed state simulated 
intestinal fluid) by the group of Dressman et al. [2]. Dissolution testing is routinely 
carried out using complete dosage forms, except for assessment of intrinsic dissolution 
testing at very early stages in drug development. In contrast to dissolution testing, 
permeability testing does not allow to address the role of formulation factors and 
excipients. Instead, permeability is considered as an intrinsic property of a given 
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compound. This may be justified by some issues arising from i) the non congruency 
between a normal dose of a solid dosage form and permeation area of the apical 
volume respectively of a Caco-2 monolayers in Transwell® system potentially resulting 
in enormous osmotic pressure differences between apical and basolateral 
compartment, ii) sheer impossibility to insert a complete dosage form into a standard 
Transwell® device, iii) non appropriate dissolution features of the apical compartment 
(volume, pH, hydrodynamics, etc.). In conclusion, researchers tend to determine two 
related and connected things separately. However, when dissolution and permeation 
assays will be connected, experimental and technical efforts therefore will definitely 
increase. So, one might ask for the benefit of the concomitant determination of 
dissolution and permeation. Three main fields of interest can be seen as follows: 
 
1.1.1 Improved in vivo - in vitro correlation for bioavailability screening of new 
API’s 
1.1.2 Improved formulation screening of innovative formulation approaches 
1.1.3 Investigation of potential food effects on drug absorption 
1.1.1 Improved in vivo - in vitro correlation for bioavailability screening of new API’s 
 
As described by Artursson at al. [3], in vitro permeability of drugs through Caco-
2 cell monolayers are correlating well with the fraction absorbed in humans. However, 
pure permeation experiments disregard possible solubility issues of a compound 
potentially limiting absorption from the gut. By combining dissolution and permeation 
assay, a deeper insight into the processes happening in vivo in the intestine may be 
given, especially if one considers the clinical dose to be dissolved in the limited 
intestinal volumes. Furthermore, dissolution testing serves as a validated tool for 
generating in vivo – in vitro correlations (IVIVC) mainly for BCS class II and IV. However, 
for BCS class III (and IV), a correlation of the dissolution signal is not necessarily given 
since dissolution may not be rate limiting and other parameters, which are not visible in 
a dissolution signal, but in the permeation process may be relevant for an IVIVC.  
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1.1.2 Improved formulation screening of innovative formulation approaches 
 
Considering the LADME model, liberation and absorption of drugs pose vital 
parameters for bioavailability after oral administration and are the only factors 
accessible for manipulation by designing adequate dosage forms. Evidently, detection 
of formulation parameters affecting dissolution processes are easier accessible than 
effects of the formulation on absorption processes. Dissolution studies have been 
shown to be a good predictor for in vivo performance of solid dosage forms, e.g. [2, 4, 
5]. under the assumption that the more compound gets into solution within an 
acceptable time in a more or less physiological surrounding, the higher the 
bioavailability or the better the in vivo performance. This central paradigm of predictive 
dissolution testing relies on the assumption that intestinal permeation is not rate limiting 
and that excipients administered along with the drug do not interfere with or alter 
intestinal epithelia. In contrast, during the past decades, more and more drugs have 
been recognized as absorbed by active cellular uptake or hindered from absorption by 
active cellular efflux systems. Simultaneously, more and more excipients have been 
detected to interact with intestinal epithelia and have been discussed as intestinal 
absorption enhancers. The mini-review of Aungst [6] and the review of Swenson et al. 
[7] may serve as an overview over that particular topic. Terao et al. [8], for example, 
reported to increase the AUC of furosemide in rats by decreasing intra luminal pH at 
distal portions of the GI by means of Eudragit L100-55, a proton releasing polymers. 
For the influx transporter PEPT1, a proton gradient coupled oligo-peptide transporter, it 
is reported that lower luminal pH values increase the driving force for the uptake due to 
a secondary uptake coupled with a proton gradient. Accordingly, Nozawa et al. [9] 
found that by decreasing the pH in the lumen of rat small intestinal by means of a 
proton releasing polymers, the bioavailability of PEPT1 substrates such as cefadroxil 
and cefixime raises. Though the authors use remarkably amount of excipient (500 mg 
excipient per kg rat weight), a proof of principle that excipients can affect active uptake 
of drugs in vivo was performed. Beside excipients improving uptake, other excipients 
are existing improving oral absorption by means of interaction with tight junctions of 
intestinal epithelia. Lindmark et al. [10] reported to possibly enhance oral absorption by 
addition of medium chain fatty acids in Caco-2 cells. Medium chain fatty acids interact 
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with tight junction proteins such as ZO-1 and occludin and increase in vitro permeability 
of the hydrophilic marker compound fluorescein-sodium. Sakai et al. [11] supported 
this theory by means of confocal laser scanning microscopy (CLSM) and by increasing 
permeability of hydrophilic, passively permeating compounds for sodium caprate and 
additionally for sodium deoxycholate. Borchard et al. [12] reported that mucoadhesive 
polymers such as chitosan-glutamate and carbomer widen tight junction indicated by 
CLSM. However, only co-administration of carbomer together with chitosan-glutamate 
leads to significant increase of permeability. Ranaldi et al. [13] found that chitosan and 
other polycations decrease TEER reversibly and increase permeability for inulin through 
Caco-2 monolayers (for a review on that particular topic see [14]).  
On the other hand, several publications are suggesting that commonly used 
surface active excipients affect cellular efflux systems, namely P-glycoprotein or other 
efflux pumps, e.g. [6, 15-21]. Many authors report increased drug fluxes from apical to 
basolateral and decreased fluxes in the adverse direction in presence of 
polyethoxylated surface active excipients such as TWEEN 80, vitamin E TPGS, pluronic 
block polymers, and Cremophor EL; whilst the mechanism of action is still under 
discussion. The application of these excipients in oral solid dosage forms affects the 
absorption process from the GI lumen in two ways. First, they can enhance dissolution 
rate by decreasing surface tension and improving wetting and by increasing solubility 
by means of micellar entrapment. Second, they can increase permeability through 
intestinal epithelia by inhibiting intestinal P-glycoprotein mediated efflux. However, these 
excipients can also decrease permeability since micellar entrapped active compound 
may no longer be thermo-dynamical active and lower fluxes may result. However, the 
findings reported in literature remain contradictory. Although statistical significant 
results in permeability assays have been found when adding such excipients in solution 
to the transport media, in vivo relevance remains questionable. Brouwers et al. [22] 
reported for amprenavir, being marketed as a dosage form (Agenerase®) with the P-
glycoprotein inferring excipient vitamin E TPGS, a much more complicated behaviour 
than generally anticipated. The authors showed that increasing concentration of vitamin 
E TPGS leads to higher dissolution rate and solubility of amprenavir in vivo. The in vitro 
permeation experiment show initially increasing and subsequently decreasing apparent 
permeabilities for increasing vitamin E TPGS concentrations, which can be due to 
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micellar entrapment above the critical micellar concentration (CMC). However, at in vivo 
relevant concentration of vitamin E TPGS and amprenivir, P-glycoprotein inhibiting 
action of vitamin E TPGS might be made irrelevant by enormous luminal concentration 
of amprenavir as a result of the surface tension lowering action of vitamin TPGS. 
Ramsay-Olocco [23] published data on a clinical evaluation of a P-glycoprotein 
substrate formulated in soft capsules along with vitamin E TPGS. Although an increase 
of flux in presence of vitamin E TGPS in absorptive direction is found in vitro, no 
significant difference is detectable in clinical studies performed in micro pigs and 
humans. In contrast, Bogman et al. [24] reported for talinolol perfused intraduodenally 
along with vitamin E TPGS a statistically increased AUC compared to talinolol 
administered alone or with Poloxamer 188, a non P-glycoprotein interfering surfactant. 
To conclude, for formulation development, it is crucial to know the actual luminal 
concentration of the API and the active excipients. Beside the increase of bioavailability, 
researchers expect by means of these excipients to lower intersubject variability of 
bioavailability normally associated with low permeability and low solubility compounds. 
Although being potent absorption enhancer in vivo, the in vivo relevance of these 
findings remains unclear. From clinical point of view, the relative contribution of 
intestinal P-glycoprotein to overall drug absorption has been questioned, unless a small 
amount of API is administrated or dissolution and permeation rate is rather low [25]. 
Additionally it was doubted whether cell culture derived in vitro data can be directly 
scaled up to humans [25]. Obviously, the in vivo relevance of P-glycoprotein is not 
depending exclusively on the affinity of the API to cellular efflux systems but also on the 
actual luminal concentration of the API and excipient. 
In this context, a combination of dissolution and permeation assessment may be 
very valuable, especially when excipients interfere at different stages in a concentration 
dependent manner. As shown above, a combined setup yielding physiological relevant 
concentrations may reveal these phenomena before testing the dosage form in animal 
and human studies. Additionally, a concept of combined dissolution/permeation might 
also be imagined to serve as a quality assurance tool for dosage forms containing 
active excipients. 
_________________________________________________________________________________________ 
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1.1.3 Investigation of potential food effects on drug absorption 
 
Effects of concomitant intake of food with drugs on disintegration [26] and 
dissolution [15, 27-31] of oral solid dosage forms are extensively described in literature. 
For dissolution testing, the development of biorelevant dissolution media by Galia et al. 
[2] simulating intestinal fluid in fed (FeSSIF) and fasted state (FaSSIF) led to a generally 
accepted in vitro method to forecast food effects in dissolution. Nevertheless, effects of 
food components on absorption processes is getting more and more in the focus of 
research [15, 32]. Wu et al. [33] suspected that concomitant intake of high fat meals 
with drugs are inhibiting intestinal in- and efflux drug transporters and thus may lead to 
decreased bioavailability of BCS class III compound; however, due to increased 
solubility in the intestinal lumen after fatty meals, BCS class II compounds may show an 
increased postprandial bioavailability. Inhibition of intestinal efflux transporters may also 
be mediated by flavonols in grapefruit and orange juice as stated in the review by 
Wagner et al. [15]. Ingels et al. [34] reported that the application of FaSSIF in Caco-2 
permeability assessment does not affect permeability of passively permeating 
compounds. However, actively secreted compounds show a significant lower 
permeability in basolateral to apical direction, whereas apical to basolateral transport is 
not affected and thus polarity in transports diminishes. Ingels et al. suggested that the 
bile salts present in FaSSIF may inhibit P-glycoprotein and other efflux transporters and 
concluded that efflux pump interference of compound detected in vitro might be 
generally overestimated. 
Consequently, an interplay between solubility and permeability with too many 
free variables is hindering the researcher or developer from clear statements. 
Interaction of food with oral absorption may happen at different stages which again can 
be titled as dissolution and permeation and a combined dissolution and permeation 
assessment might give a deeper insight in possible interaction and food effects. 
To summarize there are several rational to justify the approach for permeation and 
dissolution testing. Nevertheless, it has to be pointed out that for BCS class I and other 
“unproblematic” compounds where it can be anticipated that increased luminal 
concentrations will lead to increased transepithelial fluxes, no significant additional 
information should be expected compared the conventional dissolution testing. 
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However, for difficult compounds mainly belonging to BCS classes III and IV, vital 
information about the drug in the dosage form can be obtained. 
 
1.2 Connecting permeation and dissolution measurement assessment 
 
1.2.1 Limitations/specifications concerning permeation/dissolution media 
 
The choice of dissolution/permeation media is limited, mostly due to the need to 
maintain viability and integrity of Caco-2 cell monolayers. Main requirements of the 
media to be in contact with Caco-2 cells are: i) isotonic conditions (Caco-2 cell 
monolayers are basolaterally more sensitive to osmotic pressure than apically), ii) 
appropriate pH, which may be in a range from 5 to 8 (e.g. [35]), again this should be 
handled more restrictive basolaterally, iii) presence of calcium and magnesium ions in 
order to maintain monolayer integrity by stabilizing tight junctions, and iv) physiological 
ratio between extracellular sodium and potassium in order to warrant an appropriate 
potential difference across the epithelia. To circumvent these limitations, rendering 
dissolution media before getting into contact with Caco-2 cells may be appropriate. 
However, it has to be kept in mind that the original dissolution concentrations are 
diluted by doing so, and that the system is additionally getting more complicated. 
Therefore, one has to decide concerning the dissolution/permeation media between 
simplicity, in vivo relevance and analytical requirements. For dissolution testing, 
numerous media as described in literature, USP, or Ph. Eur., or other pharmacopoeias 
are generally accepted and mimic to some extend physiological surrounding of 
disintegration and dissolution processes. For permeation assessment, however, it still 
remains unclear which transport media generates best results. Permeability 
assessment though Caco-2 monolayers is routinely carried out using KRB (Krebs 
Ringer Buffer), KBR (Krebs Bicarbonate Ringers Buffer), or HBSS (Hanks` balanced 
salt solution), though those might pose too restrictive conditions for low soluble 
compounds due to the lack of lipids and surface active ingredients and their excessive 
amount of counter-ions. A shortcoming for low solubility compounds can generally be 
seen in the addition of either DMSO (≤ 1 %) or various other solubility improving 
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substances (a comprehend review of applied substance together with concentrations is 
comprised in [36]) For more comparable in vivo permeation conditions in Caco-2 
assays, Ingels et al. [37] recommend to employ apically FaSSIF, while basolaterally an 
analytically friendly buffer such as HBSS may be the best choice.  
Table 1.1 summarizes the composition of the previously mentioned buffer 
systems. Differences among KRB, KBR, and HBSS are not that distinct and the most 
important difference may be seen in the absence of carbonate in KRB. Degassing 
procedures prior to dissolution testing may affect the carbonate concentration and thus 
alter the pH, and therefore, KRB appears to be most suitable for combined 
dissolution/permeation measurement. 
Ingels et al. tested [37] FaSSIF and FeSSIF for compatibility with Caco-2 
monolayer integrity, prerequisite for valid permeation experiments. Only FaSSIF turns 
out to maintain Caco-2 monolayer integrity throughout three hours as indicated by 
TEER, apparent permeability of fluorescein-sodium and by means of a MTT cytotoxicity 
assay. FeSSIF is immediately toxic to the cell monolayer; Ingels et al [37] attributes this 
to the high osmolarity (≈ 600 mOsm), low pH (5.0), and the high content of Na-
taurochlate (15 mM). Additionally, the lack of glucose and especially calcium and 
magnesium, responsible for proper tight junction formation, may support monolayer 
damage. Recently, Patel et al. [38] modified FaSSIF and FeSSIF in order to obtain 
Caco-2 compatible in vivo relevant transport media. Changes of the compositions can 
be seen in Table 1. Briefly, Mg2+ and Ca2+ salts are added, osmolarity of FeSSIF is 
reduced to 330 mOsmol/kg H2O, Na
+/K+ ions are present in a physiological ratio, 
lecithin concentration in FeSSIF is doubled in order to mitigate toxicity of taurocholic 
acid and buffering phosphate and carbonate salts are added. Caco-2 monolayers 
retain their integrity throughout two hours indicated by mannitol flux and TEER. By 
means of scanning electron microscopy, no severe damage on the cells is detectable 
except a minor microvilli loss and shortening. Apparent permeability of Metoprolol is 
significantly reduced in the presence of FaSSIF/FeSSIF; the authors attribute that to 
micellar entrapment into the bile salt lecithin mixed micelles. Nevertheless, the influence 
of the modification of FaSSIF/FeSSIF on dissolution and solubilization properties of the 
media is not tested yet. 
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Table 1.1. Composition of various buffers possibly eligible for combined dissolution and permeation 
measurement. Concentrations may vary from reference to reference. Composition of FaSSIF and FeSSIF 
is shown as reported by Galia et al. [3]; in the meantime, several publications denoted a change from 
potassium to sodium as the main kation [56] or others changes. Abbreviations are given in the text body. 
afor resulting pH of 6.5: MES; for 7.4:HEPES 
 
Compound  
[mM] 
HBSS 
[36] 
KRB 
[39] 
KBR 
[38] 
FaSSIF 
[4] 
FeSSIF 
[4] 
FaSSIF 
modified 
by [38] 
FeSSIF 
modified 
by [38] 
CaCl2 1.26 1.41 1.20 -- -- 1.67 1.67 
Fumaric acid -- -- 5.40 -- -- -- -- 
KCl 5.36 3.00 4.69 103.27 203.86 5.37 5.37 
MgCl2 0.49 2.56 -- -- -- -- -- 
MgSO4 0.41 -- 1.20 -- -- 0.81 0.81 
NaCl 136.89 142.03 108.01 -- -- 136.89 136.89 
NaHCO3 4.26 -- 16.0 -- -- 0.42 0.42 
K2HPO4 -- -- 0.47 --  -- -- 
KH2PO4 0.44 -- -- 28.66 -- 0.44 0.44 
Na2HPO4 0.34 0.44 -- -- -- 0.34 0.34 
NaH2PO4 -- -- 5.38 -- -- -- -- 
Na-pyruvate -- -- 4.90 -- -- -- -- 
D-Glu 25.00 4.00 11.50 -- -- 5.55 5.55 
L-Glutamine -- -- 5.67 -- -- 2.00 2.00 
MES/HEPESa 10.0/ 20.0 
10.0/ 
20.0 -- -- -- -- -- 
acetic acid -- -- -- -- 144.17 -- -- 
Na- TC -- -- -- 3.00 15.00 3.00 15.00 
lecithin -- -- -- 0.75 3.75 0.75 7.50 
NaOH ad 7.4/6.5 
ad 
7.4/6.5 ad 7.4 ad 6.5 ad 5.0 ad 6.5 ad 6.0 
Osmolarity 
[mOsm/kg H2O] 
~ 300 ~ 300 ~ 300 ~ 300 ~ 630 343 336 
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1.2.2 Historical evolution of combined permeation and dissolution testing 
 
First attempts to combine both dissolution and permeation in one device have 
been made beginning in the mid seventies of the past century. Such typical devices 
employed distribution between three differently polar phases, i.e. the distribution 
between aqueous and lipoid and subsequent between lipoid and again aqueous 
phase, whereas both aqueous phases were kept apart by baffles. Thereby, a 
compromise that had to be accepted resulted from the fact that the “membrane” (i.e. 
the lipoid phase) was much thicker than the in vivo membranes and transport rates 
found in vitro appeared to be too strongly controlled by that. In 1969, Dibbern et al. [40, 
41] circumvent this drawback by separating both aqueous acceptor and donor phase 
by lipoid treated polymeric membranes and thus was able to improve prediction of in 
vivo behaviour of dosage forms containing passively permeating compounds (the 
apparatus became commercially available under the name “Resomat” of the company 
Desaga). However, the validity of the obtained data was limited due to the employment 
of artificial lipoid membranes and thus omitted conclusions concerning actively 
secreted or absorbed drugs and metabolism. In 1980, Koch et al. [42] reported a 
simplified experimental tool (“Resotest Apparatus”) again reviving the experimental 
determination of the partition between organic and aqueous phases. However, the 
apparatus was reduced to a rotating two-necked pear shaped flask containing two 
aqueous phases conjointly covered with a layer of suitable organic solvent. Although 
being a crude simplification and exhibiting non-physiologic lipoid membrane, the model 
made it into the textbooks; maybe because it was very easy to handle due to its 
simplicity. However, none of the dissolution-permeation devices were listed in the 
pharmacopoeias. As computing power, however, started to increase tremendously 
from the early 1980’s and computational modelling sciences emerged, those simplified 
models for dissolving and passively permeating substances became obsolete. 
In the meantime, dissolution testing was more and more standardized and 
gained enormous impact on the fields of quality assurance and drug development in  
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pharmaceutical industry. Several dissolution apparatus made their way into the 
pharmacopoeia such as the rotating paddle, rotating basket, reciprocation cylinder and 
the flow through cell, just to mention the most important. For comprehensive discussion 
on dissolution equipment, the reader is referred to books such as [43]. 
At the beginning of the 1990’s, the general acceptance of Caco-2 cell 
monolayers as a model of the small intestinal mucosa caused a significant push toward 
 
 
Figure 1.1. Microscopical depiction of Caco-2 cell (clone C2bB1), 21 days post seeding, 1000 fold 
magnification, staining left picture: haematoxylin (nuclei), right picture: alcium blue (mucus/microvili) + 
nuclear red (nuclei), detached from membrane. 
 
the field of permeability testing [44, 45]. Caco-2 cells, originally derived from a colon 
cancer patient, differentiate spontaneously on cell culture supports to small intestinal 
epithelia like cells. Although lacking significant mucus production, it was found that 
permeability through Caco-2 cells correlates well with human intestinal permeability [3] 
and ultimately the Caco-2 cell line (Figure 1.1) was generally accepted as a powerful 
in vitro tool to forecast oral drug absorption. As a consequence, the pharmaceutical 
community became more aware that permeation through intestinal epithelia is 
oftentimes more than mere diffusion through a lipophilic membrane. 
In 1995, Amidon et al. [46] addressed a theoretical base for a biopharmaceutic 
drug classification, which was also addressed in several FDA guidelines [47, 48]. The 
biopharmaceutical classification system (BCS) assigns drugs into classes I to IV 
according to their solubility and permeability properties; thus highlighting the 
importance of both fundamental parameters – dissolution and permeation; nowadays, 
the BCS has gained tremendous impact on drug development. 
_________________________________________________________________________________________ 
Introduction 
1-13 
1.3 Published approaches for permeation and dissolution assessment 
 
Recently, an approach mimicking the GI tract and feasible for pharmaceutical 
dissolution studies has been published [49]. Coming from the area of nutritional 
research, this approach reflects some promising aspects such as relevant luminal pH 
values, peristalsis, luminal bacterial colonization, and relevant volumes. However, 
permeation is only reflected by diffusion through hollow fiber membranes and thus is 
not in the scope of this chapter. Nevertheless, it will be interesting to see whether it will 
be possible to expand such perfect in vitro device with intestinal epithelia. 
Several approaches combining Caco-2 permeation assessment with dissolution 
testing have been published. In the following, the systems are described in 
chronologically order of their publication. 
 
1.3.1 Approach by Ginski and Polli [50] 
 
In 1999, Ginski et al [50] published a continuous dissolution/Caco-2 system. 
Dissolution takes place in a paddle apparatus (apparatus I, USP) and Caco-2 
monolayer is mounted in a side-by side diffusion cell whereas a peristaltic pump 
transfers media from the dissolution vessel to the permeation chamber. Dissolution and 
permeation media is HBSS (pH 6.8). The system (Figure 1.2) can be seen as a closed 
model, since no drug was allowed to leave the experimental setup.  
 
 
Figure 1.2. Approach of Ginski and Polli. 
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The study had several objectives. Main objective was to test whether the 
experimental data fit to the previously described mathematical model determining the 
dissolution/absorption relationship [50, 51]. Another objective was to detect possible 
effects of the formulation (disintegrating agent, solubilizers such as TWEEN 80 and 
cyclodextrins) on the dissolution/absorption relationship. Although being a rather simple 
experimental setup, the results were promising. Ginski et al. were able to confirm the 
validity of their setup with in vivo data using piroxicam and ranitidine oral solid dosage 
forms with varying release kinetics. The addition of croscarmellose-Na as an in vitro 
permeation enhancing agent leads to an increased permeated amount through Caco-2 
cell monolayer; although in vivo no absorption enhancing effect of croscarmellose-Na is 
detected. This phenomenon is attributed to the calcium sequestering properties of 
croscarmellose-Na and is identified as a false positive in vitro finding, since complete 
sequestering of all extracellular calcium may not happen in vivo. For the variation of 
solubilizers the authors prove that only dissolution is altered, not permeation. Finally, 
the authors concluded that this continuous dissolution/Caco-2 may be a tool to 
forecasting formulation effects on in vivo dissolution and in vivo permeation.  
 
1.3.2 Approach by Miyazaki et al. [52-55] 
 
Shortly after Ginski et al., Kobayashi et al. [52] published in 2001 an open 
dissolution/permeation approach. A stirred glass vessel serves as a flow through 
dissolution device, from whose the eluted solution is pumped into second glass vessel 
for pH adjustment. Subsequently to neutralizing to a pH of 6.0, the eluted solution is 
transferred into a flow through diffusion chamber with a Caco-2 monolayer between the 
acceptor and donor compartment. A schematical drawing of the most recently 
published setup is shown in Figure 1.3. The authors routinely carry out their experiment 
with a HBSS like buffer, which is generated prior to contact of the buffer with the Caco-2 
monolayers. The system is able to simulate various pH values acting on the drug, 
however, the device is not capable of changing pH acting on the drug in one 
experiment and thus one might argue that in vitro, the undissolved drug appears to stay 
in gastric compartment rather than being transferred to the small intestine with its 
increasing pH values. This issue is almost circumvented in later publications by 
_________________________________________________________________________________________ 
Introduction 
1-15 
employing several gastric acidic models [54]. Nevertheless, the authors are able to 
mimic precipitation of weak bases in the “ph adjustment vessel” such as for albendazol 
[55]. Furthermore, the apparatus of Kobayashi et al. [52] and He at al. [53] shows a 
good linear relationship between the amount cumulatively permeated into the acceptor 
compartment and the fraction absorbed in humans although clinical doses of the drugs 
are disregarded. Interestingly, the authors used this system also for assessing 
metabolism of prodrugs to be cleaved in intestinal cells, for instance 
ampicillin/pivampicillin. The experiments with either rat intestine or Caco-2 monolayers 
indicate that pivampicillin is undergoing cleavage during the permeation through the 
intestinal barriers and again the obtained values correlated well with in vivo data. 
 
 
Figure 1.3. Approach of Kobayashi et al.. 
 
In comparison to the approach of Ginski et al. [50], the approach appears to be 
more elaborate and complex and is coming closer to in vivo reality. The device can 
simulate various effects of pH on dissolution and is, as an open system, closer to in vivo 
conditions compared to a closed one. However, it exhibits the drawback of not freely 
“adjustable” pH values acting on the drug. Low flow rate in the dissolution vessel may 
limit applications of complete dosage forms and allows predominantly only the use of 
granules, pellets or grinded tablets. Additionally, the application of compendial 
dissolution devices appears to be a more robust approach.  
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1.3.3 Aproach by Kataoka et al. [56, 57] 
 
In 2003, Kataoka et al. [56] published an in vitro system for simultaneous 
evaluation of dissolution and permeation of poorly water soluble drugs. In contrast to 
Ginski et al. [50], this system assesses dissolution and permeation in a downsized 
dissolution vessel (one percent of the volume estimated in vivo, 8 ml) with a Caco-2 
monolayer mounted between acceptor (5.5 ml) and donor compartment (Figure 1.4). 
When reducing the volumes to a hundredth, the dose of the drug has also to be 
reduced by the same scale, which may raise some balancing and handling issues 
when adding 0.1 mg drug or even less to the dissolution compartment. In comparison 
to previously published paper, the authors highlight the importance of clinical doses of 
the compounds tested, as also compounds are assigned into the four BCS classes 
[46] according to their solubility of the highest dose in 250 ml. The authors find a good 
correlation between the amount permeated after 120 min and the fraction absorbed in 
humans, whereas the 120 min time point was chosen in regard to the mean small 
intestinal transit time.  
 
 
Figure 1.4. Approach of Kataoka et al.. 
 
The setup was additionally able to assign correctly all compounds into BCS 
classes I-III; however, the study was lacking a BCS class IV compound. Furthermore, 
experiments applying apically 5 mM taurocholate (ranges between FaSSIF and FeSSIF) 
in the dissolution compartment showed increased permeated amount for griseofulvin, 
mainly due to higher dissolution rate and solubility. Also the addition of 4.5 % BSA in the 
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acceptor compartment increased the permeation rate of griseofulvin which may be 
attributed to increased sink conditions. In 2006, Kataoka et al. [57] focussed on 
predicting effect of food intake on oral drug absorption in humans. Therefore, Kataoka 
and coworkers tested various kinds of simulated intestinal fluids in their 
dissolution/permeation setup and successfully correlated their results with human in 
vivo data. Additionally, they could visualize the interplay between food effect and 
formulation properties. 
The approach of Kataoka et al. [56, 57] shows desirable features such as 
downsized, in vivo relevant volumes and low efforts for devices and thus low error 
proneness. Additionally, application of in vivo relevant dissolution/permeation media 
increased the predictive power of the dissolution/permeation system impressively. 
Nevertheless, the device lacks the possibility to add complete dosage forms and the 
use of compendial dissolution devices would be a more robust approach. 
 
1.4 Critical evaluation of the state of the art and aims of the study 
 
To connect two in vitro assays displaying fundamental processes occurring 
during oral absorption in vivo, appears to be a promising tool. Such setup allow the 
researcher intense comprehension of the interplay of dissolution and permeation with 
surrounding media and excipients. However, the following improvements would have to 
be made in order to improve the value of the obtained data.  
In view of the published approaches, the author points out that an open 
dissolution system will generate concentration time trends with higher in vivo relevance 
since the drug will not accumulate at the donor site throughout the experiment 
(compare [50, 56, 57]). In an open system, drug concentration will reach high values 
and hence potentially saturate transporters or overrun efflux transporters at these 
concentrations. However, after the peak concentrations were reached, uptake or efflux 
transporter affinity is getting relevant again. In a closed system, drug concentration will 
increase and saturate transporters until the experiment is terminated.  
A second focus of the work will be placed on the ability of the apparatus to use 
complete dosage forms. As already stated in section 1.1.2 (p 1-4), excipients might 
affect both dissolution and permeation; hence, permeability assessment should not 
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neglect the presence of excipients. As a consequence, the apparatus to be developed 
throughout this dissertational project should be capable of assessing dissolution and 
subsequent permeation of complete dosage forms. Although Miyazaki et al. [52-55] 
applied an open dissolution and permeation system, their system lacks the ability to 
use complete solid oral dosage forms. Furthermore, a modular, depressurized setup 
will allow the application of compendial dissolution pumps providing appropriate 
hydrodynamics for dissolution. As a consequence from the aim to use complete 
dosage forms, also in vivo relevant flow rates have to be used resulting in in vivo 
relevant dissolution volumes. 
In conclusion, the aim of the study was to develop a test system with the ability 
to assess permeability of solid oral dosage forms in an open dissolution and 
permeation system. Moreover, it was intended to plan the system as a modular setup 
increasing the simplicity and reliability of the apparatus.  
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2 Proof of concept  
 
 
In order to proof the concept based on the implications made in chapter 1, the 
apparatus has been tested using varying dosage strengths and release kinetics of 
propranolol HCl tablets. Propranolol HCl has been chosen as a model drug 
because of its high solubility and permeability. Data obtained from those tablets 
has been checked concerning plausibility and conclusiveness. 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this section have been published in  
 
Motz SA, Schaefer UF, Balbach S, Eichinger T, Lehr CM. Permeability assessment for solid oral drug 
formulations based on Caco-2 monolayer in combination with a flow through dissolution cell, Eur. J. 
Pharm. Biopharm. (2007), doi:10.1016/j.ejpb.2006.10.015 [39] 
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2.1 Introduction 
 
Among the various setup addressed in the previous section, the most promising 
approaches have been combined. Hence a conventional dissolution setup was chosen 
according to the approach of Ginski et al.[50]. Having dynamic concentration changes 
on the apical surface of the Caco-2 monolayer with an open dissolution device led to 
the employment of the dissolution apparatus 4, USP [58]. Additionally, according to 
Kataoka et al., the clinical doses were taken into consideration and this also accounted 
for the apparatus 4 which is able to mimic physiological relevant volumes and 
hydrodynamics. In order to mitigate analytical issues when assessing the permeated 
amount, the acceptor compartment was designed to be closed. 
 
O OOH
COONa
 
Figure 2.1. Chemical structure of fluorescein-Na 
 
Prior to testing complete dosage forms, it was investigated if the flow through 
permeation cell (FTPC) provides comparable results for permeation data compared to 
static experiments performed in conventional Transwell® systems. For this purpose, 
two different compounds were tested: propranolol as a high permeability marker 
(marker for unstirred water layers) and fluorescein-Na as a low permeability marker 
(marker for barrier integrity). For the permeation module, several criteria have to be 
matched such as i) the integrity of the Caco-2 monolayer has to be maintained 
throughout the experiments and ii) conditions for permeation should be comparable to 
those in Transwell® systems. 
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Figure 2.2. Chemical structure of propranolol 
 
Propranolol HCl was chosen because of its biopharmaceutical properties: It 
shows high permeability in Caco-2 transport experiments [59] and human perfusion 
studies [60]. Caco-2 transport experiments indicate that propranolol is permeating 
mainly transcellular and neither has affinity to cellular efflux nor to influx systems [59, 61, 
62]. In addition, propranolol HCl is highly soluble in aqueous buffers [59, 63] and hence 
is assigned to BCS class I [33, 59, 64]. 
In order to test and validate the newly designed combined apparatus, 
propranolol HCl released from a solid dosage forms at different dosage strengths was 
used. Beyond that, extended release propranolol HCl tablets with varying amounts of 
Eudragit® NE 30D as a retarding agent were produced. For propranolol, increase of 
dosage strength should lead to a direct proportional increase of permeation; retardation 
of release should lead to a direct change of the appearance rate in the trans-mucosal 
receptor compartment. Up to now, no other in vitro setup has been described that 
would allow to monitor the impact of such formulation related parameters on the 
intestinal permeability of a drug formulated as solid oral dosage form. Critical 
parameters in this “proof of concept” were i) Caco-2 cell monolayer integrity, ii) the 
handling, iii) reproducibility, and iv) conclusiveness and plausibility of the obtained data.  
 
2.2 Material and Methods 
 
2.2.1 Materials 
 
Transwell® permeable filter inserts (pore size 0.4 µm, 1.13 cm2, Transwell® type 
3460) were purchased from Corning Incorp. Life Sciences (Acton, MA). Dulbecco’s 
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modified Eagle’s medium (DMEM), non-essential amino acids (NeAA) and fetal bovine 
serum (FBS) were purchased from GIBCO (Invitrogen Corp. Carlsbad, CA). 
Fluorescein-Na was purchased from Sigma-Aldrich (St. Louis, MO), and propranolol 
HCl from Synopharm GmbH & Co KG (Barsbüttel, GE). Organic solvents were of HPLC 
grade. Eudragit® NE 30 D was a kind gift from Degussa. (Röhm Pharma Polymers, 
Darmstadt, GE). Avicel PH 102 was from Lehmann & Voss (Hamburg, GE); Lactose EP 
type D20 was from J. A. Meggle Milchindustrie (Reitmehring, GE); PVP insol. was from 
BASF (Ludwigshafen, GE); Aerosil 200 was from Degussa (Rheinfelden, GE); Mg- 
Stearate was from Synopharm GmbH & Co KG (Barsbüttel, GE). All tablet excipients 
were of Ph. Eur. grade. All salts for KRB were of cell culture tested grade and obtained 
from Sigma-Aldrich (St. Louis, MO). 
 
2.2.2 Cell culture 
 
Caco-2 cells, clone C2BBe1, were purchased at passage 60 from American 
Tissue Culture Collection (ATCC; Manassas, VA) and used at passages 70-92. Caco-2 
cells were grown to ~90 % confluency in 75 cm2 T-flasks with DMEM supplemented 
with 10% FBS and 1% non essential amino acids (NeAA). Culture medium was 
changed every second day. The incubator temperature was set to ~37°C in an 
atmosphere of ~85 % relative humidity and ~5% CO2. After trypsinisation, cells were 
seeded on Transwells® at a density of 60,000 cells/cm2. Transepithelial electrical 
resistance (TEER) was measured routinely (EVOM, World Precision Instruments, Berlin, 
Germany) and only monolayers with a TEER > 350 Ω·cm2, with background for plain 
filters subtracted, were used for transport studies. 
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2.2.3 Transport assay 
 
Caco-2 monolayers were used 21-25 days post seeding. Prior to transport 
experiments, DMEM with supplements was removed and KRB pH 7.4 was added to the 
apical and basolateral compartment. 
Apparent permeability (Papp ) was calculated according to Eq (1):  
 
Papp = 
dQ
dt  · 
1
A-c0
       Eq (1) 
 
whereas A [cm2] is the nominal surface area of the monolayer and c0 [µg/ml] is the 
donor concentration at t = 0 h. The quotient dQ/dt was calculated from the slope of the 
linear part of the mass increase in the acceptor compartment. Concentration of 
propranolol HCl in the donor compartment was 30 µg/ml and 10 µg/ml for fluorescein-
Na, respectively. Integrity of the Caco-2 monolayers was checked microscopically and 
by measuring TEER values before and after the experiments. Donor solutions were 
pumped into the FTPC with a flow rate of 1.0 ml/min and samples were withdrawn from 
the circulating basolateral compartment after 30, 60, 90, 120, 150, 180 and 210 min. 
Retrieved volumes were replenished with fresh KRB (n = 5 for both compounds). The 
retrieved amount of propranolol HCl from the basolateral compartment was taken 
mathematically into consideration (please see Eq(2)). 
 
cn corr = 
[c1ΩV+c2ΩV+...+cnΩV]+cnΩV
Vbas
     Eq (2) 
 
whereas cn is the concentration measured at measurement time n [µg/ml], V is the 
sampling volume [ml], while Vbas is the volume of the complete basolateral compartment 
[ml]. 
 
2.2.4 Preparation of tablets 
 
Immediate release tablets (IR tablets) were manufactured using direct 
compression (for formulation see Table 2.1). Ingredients were sieved (mesh size 
315 µm), blended in an turbula mixer (TS Bachofen, Basel, Switzerland) and 
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subsequently compressed using a Korsch EK 01 (Berlin, GE) eccentric tablet press 
gaining tablet mass of 100 mg and crushing strength of 100 N (Erweka hardness tester, 
type TBH 30M, Erweka, Heusenstamm, GE). 
 
Table 2.1. Composition of the immediate release propranolol HCl (IR) tablets 
 
 5 mg 10 mg 20 mg 
Avicel PH 102 70 % 70 % 70 % 
Lactose EP type D20 23 % 17 % 7 % 
PVP insol. 1 % 1 % 1 % 
Aerosil 200 1 % 1 % 1 % 
Mg- Stearate 1 % 1 % 1 % 
Propranolol HCl 5 % 10 % 20 % 
 
Extended release tablets (ER tablets) were prepared as follows (for formulation see 
Table 2): lactose, Avicel and propranolol HCl were granulated using a 30 % dispersion 
of Eudragit® NE 30D. Water was added until a capable granulate was formed. 
Subsequent to sieving trough a 2 mm sieve, the wet powder was dried for 1 hour 
 
Table 2.2. Composition of the extended release propranolol HCl (ER) tablets 
 
Eudragit® NE 30 D ++ 4 % 8 % 
Avicel PH 102 55 % 55 % 
Lactose EP type D20 29 % 25 % 
Propranolol HCl 10 % 10 % 
Water q. s. q. s. 
   
Aerosil 200 1% 1% 
Mg- stearate 1% 1% 
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in an oven with circulating air at 45 °C followed by an over night drying at room 
temperature. Shortly before compressing, freshly sieved Aerosil 200 and Mg- stearate 
were added and blended for 5 min in a turbula mixer. Tablets were produced with a 
mass of 100 mg and a crushing strength of 100 N.  
Content uniformity was determined by dissolving a tablet in 100.0 ml water by 
means of ultrasonic. Then, the solution was filtered through a 0.22 µm PTFE filter 
(Optiflow®, WiCom GmbH, GE) via a 5 ml syringe (Braun, Melsungen, GE), whereas the 
first eluted drops were discarded. Subsequently, the filtrated solution was diluted with 
water (1:20) and the concentration was assessed via HPLC. For each dosage strength 
and release property, ten tablets were tested. 
 
2.2.5 Preparation of Krebs Ringer Buffer (KRB) 
 
Krebs Ringer Buffer (KRB) was prepared by adding 1.41 mM CaCl2, 2.56 mM 
MgCl2, 142.03 mM NaCl, 0.44 mM K2HPO4, 4.00 mM D- Glucose and 10.0 mM HEPES 
to 5 liter of Millipore® water. The pH was adjusted by means of concentrated NaOH 
solution to 7.4 ± 0.1. Subsequently, the buffer was filtrated through a 0.22 µm filter into 
sterilized glass vessels in a laminar flow bench warranting sterility of the buffer. The 
buffer was could be used for maximum 2 weeks. Prior to experiments, the KRB was 
degassed by means of ultrasonic. 
 
2.2.6 Analytics 
 
2.2.6.1  Propranolol HCl 
Quantification of propranolol HCl was performed using a Dionex HPLC system, 
implemented with a RP 18 (LiChroSpher® 100, Merck), 5 µm, 12,5 cm column. The 
HPLC system consisted of a Dionex P580 pump, a Dionex ASI 100 auto sampler, a 
UVD 170 S detector and a Dionex STH 585 column oven. Software was Chromeleon® 
6.60, SP 1 build 9.68. Mobile phase for Propranolol quantification was 45% (v/v) water, 
22% (v/v) acetonitrile, 33% (v/v) methanol, 0.033% (v/v) triethylamine and 0.044% (v/v) 
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phosphoric acid. Flow was 1.2 ml/min and oven temperature was 40 ± 1 °C. Detection 
was done with UV at 215 nm, whereas linearity (R> 0.999) was given between 30 ng/ml 
and 100 µg/ml. Retention time was 3.00 ± 0.15 min. It was shown that neither the 
excipients of the tablet nor salts of KRB interfered with the analysis.  
 
2.2.6.2  Fluorescein-Na 
Quantification of fluorescein-Na was performed using the native fluorescence in 
a Cytofluor II fluorescence reader (λexc = 485 nm, λem = 530 nm) with Cytofluor software 
version 4.2 (PerSeptive Biosystems, Wiesbaden- Norderstedt, GE). Measurement took 
place in a 96 well plate and was done after addition of 150 µl 10 mM NaOH to 50 µl 
analyte in order to assure higher fluorescence levels and to minimize pH triggered 
fluorescence intensity changes. Linearity (R > 0.999) was given between 5 ng/ml and 
1 µg/ml.  
 
2.2.7 Data treatment 
 
All data is given as mean ± standard deviation. Statistical analysis has been 
done using Sigma Stat for Windows version 3.0.1 build 3.01.1.  
Calculation of mean times for the different sampling port was done according to Eq (3) 
to Eq (5). 
 
mean time at D     : MTD = 
(tΩmD) - AUCD
mD
    Eq (3) 
mean time at A     : MTA = 
(tΩmA) - AUCA
mA
    Eq (4) 
mean time at B     : MTB = 
(tΩmB) - AUCB
mB
    Eq (5) 
 
t is the time duration over which dissolution or permeation was measured, mD and mA 
are the masses which cumulatively appeared at the respective sampling port after time 
t, mB is the mass which permeated and was detected at sampling port B after time t. 
AUCD, AUCA, and AUCB are the areas under the curves for the respective sampling 
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ports (all areas were calculated using trapezoidal rule). The withdrawn amount in the 
basolateral compartment was taken into consideration when calculating the permeated 
amount according to Eq(2). For regression, Sigma Plot 2004 for Windows Version 9.0 
was used (values are given as mean ± std error). 
 
2.3 Results 
 
2.3.1 General consideration in respect to the apparatus 
 
The apparatus can be divided into two modules: a flow through permeation 
module and a flow through dissolution module, whereas both modules are connected 
by means of a stream splitter (Figure 2.3, Figure 2.5). In the permeation module, flow 
rate was set to 1.0 ml/min and in the dissolution module to 6.5 ml/min. The flow through 
permeation module can be subdivided into two compartments: the open apical and the 
closed basolateral compartment with a Caco-2 monolayer upon a Transwell® mounted 
between these both compartments. Within the basolateral compartment, a magnetically 
stirred glass vessel was installed for sampling and for setting up a supply for KRB 
buffer. Sampling was performed at three different locations, designated in Figure 2.3 as  
 
Figure 2.3. Schematical depiction of the apparatus for combined flow through measurement of 
dissolution and permeation (* flow = 6.5 ml/min; ** flow = 1.0 ml/min). Sampling ports are indicated with 
capitals: D, sampling port dissolution; A, sampling port apical, B, sampling port basolateral. 
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“D” – dissolution, “A” – apical, and “B” - basolateral. The flow through dissolution 
module consisted of the USP apparatus 4 (flow through cell, Sotax CE1, Sotax, GE) 
equipped with a 12 mm dissolution cell and a filter preventing undissolved solids from 
escaping. Tablets were placed upon small glass beads as described in <724> of USP 
(25). Samples taken at “D” represent the dissolution process, samples collected at “A” 
 
 
Figure 2.4. Depiction of the flow through permeation cell (FTPC) with a Transwell® inserted shown in red. 
The apical compartment is in the left side, whereas the basolateral compartment is in the right side. 
 
represent the amount and extent of drug, which appeared in the apical compartment of 
the FTPC (Figure 2.4) being available for permeation through the Caco-2 monolayer 
(Sample volume at “D” was 0.5 ml, and 150 µl at “A”, resp.). Since the basolateral 
compartment of the permeation module is a closed compartment, the retrieved 
samples were replenished with blank KRB buffer (Sample volume at “B” was 150 µl). 
The complete volume in the basolateral compartment was calculated and 
experimentally confirmed as 10.5 ml. In order to avoid any issues concerning 
adsorption and biocompatibility, the tubing (ID 1.0 or 2.0 mm) consisted of Teflon®, and 
the FTPC (Figure 2.4) and the stream splitter (Figure 2.5)  were made of 
polyetheretherketone (PEEK). All streams in the apparatus were driven by membrane 
dosage pumps of type Stepdos 03® (KNF Neuberger, Freiburg, GE) in combination with 
pulsation dampers. The apparatus 4 and the flow through permeation cell were 
submersed in a water bath and heated to 37.0 +/- 0.5 °C. Prior to each experiment, 
Caco-2 monolayers were washed twice with KRB and equilibrated in KRB for at least 
30 min in an incubator. After that, transepithelial electrical resistance (TEER) was 
measured, the Transwell® was subsequently inserted in the FTPC, and cells were 
allowed to equilibrate for another 15 min with an apical and basolateral flow of each 
1.0 ml/min. After the experiments, Transwells® with the Caco-2 monolayer were taken 
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out of the FTPC and integrity of the Caco-2 monolayer was confirmed microscopically 
and again by TEER measurement. 
 
 
Figure 2.5. Schematical depiction of the stream splitter. The dissolution stream is led into the top of the 
device, whereas two pumps are aspirating the adjusted volumes per time from the underneath. 
 
To allow the option of different media and flow rates, the dissolution and permeation 
module requires the use of a stream splitter (Figure 2.5) which supplies the permeation 
module with appropriate low flow rates to ensure viability and integrity of Caco-2 
monolayers. The two modules are hydrodynamically separated, and thus can be run 
independently. Therefore, pressure variations in the dissolution module possibly caused 
by pumps and clogged filters do not carry over into the permeation module where 
pressure sensitive Caco-2 cell monolayers are located. Technical details of the stream 
splitter and the FTPC are given in Figure 8.3, Figure 8.4, Figure 8.5, and Figure 8.6, 
respectively. The open apical compartment of the permeation module led the stream 
with the dissolved drug to the waste after it has passed through the FTPC, whereas the 
basolateral compartment is a closed compartment. This setup entails that a peak 
concentration time profile generated in the dissolution module can also be detected in 
the apical compartment as a peak concentration profile in the permeation module. 
However, this peak profile is altered to a sigmoid concentration time profile in the 
basolateral compartment of the permeation module. The rationale to implement a 
circulating basolateral compartment are the higher concentrations compared to those 
in an open compartment, i.e. facilitating analytics of the permeated drug. 
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2.3.2 Effects of flow rate in the FTPC on Papp of propranolol and fluorescein-Na 
 
Papp values of propranolol HCl and fluorescein-Na were assessed with the FTPC. 
For an apical flow rate of 0.75 ml/min, Papp of propranolol HCl was determined as 2.2·10
-
5 cm/s. Apical flow rate of 1.25 ml/min led to an Papp of 2.9·10
-5 cm/s, flow rate of 
1.00 ml/min led to an Papp of 2.5 ± 0.52·10
-5 cm/s (n=4) At 1.00 ml/min, Papp of 
fluorescein-Na was 4.7·10-7 cm/s. For the flow rates of 0.75 – 1.25 ml/min, TEER values 
measured after the experiments remained above 350 Ω·cm2 and monolayer were 
microscopically intact. Flow rates above 2 ml/min showed deleterious effects on Caco-2 
cell monolayers. 
 
2.3.3 Assessment of drug permeability and dissolution at different dosage strengths 
 
Three immediate release tablet batches with increasing amount of propranolol 
HCl were investigated. The concentration time profile measured at sampling port D and 
at A is shown in Figure 2.6. The dissolved amount after 120 min calculated by means of 
trapezoidal rule yielded for all three batches 90 % of the labelled amount or more (not 
shown). 5 and 10 mg IR propranolol HCl tablets showed a rather rapid release of 
propranolol and exhibited a peak concentration at approximately 10 min at sampling  
port D and at 15 min at sampling port A. The 20 mg immediate release propranolol HCl 
tablets showed a slightly delayed initial release of propranolol HCl with a shoulder and 
subsequently reached maximum peak concentration at about 23 min at sampling port 
D and approximately 30 min at sampling port A. In the lower plot of Figure 2.6, a 
sigmoid time curve of permeated propranolol HCl was observed. Since the volume of 
the basolateral compartment was experimentally determined as 10.5 ml, the permeated 
amount could easily be assessed from the measured concentrations. The permeated 
amount after 120 min was significantly different for all propranolol HCl tablets (ANOVA, 
Holm-Sidak test, p < 0.001). 
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Figure 2.6. Concentration time trends for immediate release tablets at sampling port D and A (upper and 
middle plot). Lower plot shows the permeated amount calculated from the concentrations assessed at 
sampling port B. Closed circles (●) represent 5 mg, open circles (○) represent 10 mg and triangles down 
(▼) represent 20 mg immediate release propranolol HCl tablets (mean +/- st dev, n = 4-5 for each 
dosage strength). 
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2.3.4 Assessment of drug permeability and dissolution at different release kinetics 
 
Three different tablet species with differently retarded 10 mg propranolol HCl 
were investigated. Retardation was mediated by increasing amounts of 
Eudragit® NE 30D. Note that sampling time was prolonged for the extended release 
tablets from 120 min to 180 min. The concentrations at sampling port D and A are 
shown in Figure 2.7. Concentration profiles of the immediate release and the two 
retarded tablet species can easily be distinguished from each other Figure 2.7 since 
retardation led to decreased maximum concentration and flattened peaks. The 
cumulative release after 180 minutes based on the AUC was for each, the immediate 
release and the 4% Eudragit® NE 30 D containing extended release tablet, greater than 
90 %, whereas the 8% Eudragit® NE 30D containing extended release tablet released 
about 82 % of the labelled amount within the time of the experiment. In summary, the 
addition of Eudragit® NE 30D led to an evident, concentration dependent retardation of 
release of propranolol HCl. Obviously, and as expected for a highly permeable 
compound, the appearance of propranolol HCl in the basolateral compartment of the 
permeation module is governed by its concentration at the apical side of the 
permeation device which depends on the release rate from the dosage form (Figure 
2.7, lower plot) 
 
2.4 Discussion 
 
2.4.1 Rationale for the particular setup and choice of media, flow rates, and 
formulations 
 
To allow the option of different media and flow rates, the dissolution and permeation 
module requires the use of a stream splitter which supplies the permeation module with 
appropriate low flow rate and thus can be run independently. Therefore, pressure 
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Figure 2.7. Concentration time trends for extended release tablets at sampling port D and A (upper and 
middle plot). Lower plot shows the permeated amount calculated from the concentrations assessed at 
sampling port B. Closed circles (●) represent the 10 mg propranolol HCl immediate release tablet, open 
circle (○) represent the 10 mg extended release tablet with 4 % Eudragit® NE 30D and triangles down 
(▼) represent the 10 mg extended release tablet with 8 % Eudragit® NE 30D (mean +/- st dev, n = 4-5). 
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variations in the dissolution module flow rates to ensure viability and integrity of Caco-2 
monolayers. Since the stream splitter works depressurized, effects on the dissolution in 
the flow through dissolution cells are highly unlikely and have not been detected. Both 
modules are hydrodynamically separated, possibly caused by pumps and clogged 
filters do not carry over into the permeation module where pressure sensitive Caco-2 
cell monolayers are located. The rationale to implement a circulating basolateral 
compartment are the higher concentrations compared to those in an open 
compartment, i.e. facilitating analytics of the permeated drug.  
Working with sensitive cell culture models such as Caco-2 cell monolayers puts 
limitations on the use of the aqueous media to be in contact with them. Viability and 
integrity of a Caco-2 monolayer depends, just to mention some important parameters, 
on iso-osmotic pressure in combination with appropriate pH values, and thus choice of 
dissolution media is very limited when the liquid with the dissolved drug is directly led 
over the Caco-2 monolayer. Although it has been reported that HBSS like buffers tend 
to underestimate solubility of drugs due to its high hydrophilicity and its excessive 
content of possible counter-ions [37], KRB was chosen as both dissolution and 
permeation buffer since for the model drug propranolol HCl no solubility issues are 
expected. The pH for dissolution and permeation measurement was chosen to be 7.4, 
although pH in the small intestine is reported to be one magnitude lower. However, the 
authors wanted to avoid any issues arising from false efflux phenomena for weak bases 
as it has been described by Neuhoff et al. [35]. Moreover, applying cell culture 
compatible biorelevant dissolution media was beyond the scope of this first evaluation 
of our new apparatus. 
The flow rate in the dissolution module was set to 6.5 ml/min for two reasons: first, 
volumes in the small intestine accessible for dissolution of orally administered drugs are 
generally regarded to be between 120 and 350 ml for the fasted state and up to 
1600 ml for the fed state [65-67]. For the here described setup, an experiment time of 
120 or 180 min combined with a flow rate in the dissolution module of 6.5 ml/min 
yielded total volumes of 780 or 1170 ml and are ranging within the above mentioned 
physiological limits. The second reason was that concentration of propranolol HCl 
resulted in a physiologically relevant magnitude. Assuming an administration of 10 mg 
of propranolol HCl dissolving in 200 to 250 ml of intestinal fluid, a concentration of 40 to 
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50 µg/ml would be yielded. Maximum concentrations in the apparatus for the 10 mg 
immediate release tablet of 50 to 60 µg/ml do fit well to the estimated values.  
For selection of the flow rates in the permeation module, the determination of 
Papp was essential. For comparison, the Papp obtained with a flow rate of 1 ml/min in the 
FTPC and the Papp obtained with static conditions as reported in literature are shown in 
Table 2.3. Since permeation of highly permeable compounds, such as propranolol HCl, 
may be limited by stagnant water layers adhering to membrane surfaces [68], a 
comparable Papp for propranolol HCl is of vital interest in order to assure comparable 
hydrodynamic  
 
 FTPC [cm/s] (n=4) Papp reported in literature [cm/s] 
propranolol HCl 2.5 ± 0.52·10-5 1.1 ± 0.5 - 4.3 ± 0.4·10-5  [59] 
fluorescein-Na 4.7 ± 0.57·10-7 2.1 - 4.0- 5.86 - 6.23·10-7  [10, 11, 69, 70] 
 
Table 2.3. Comparison of apparent permeability values assessed with the FTPC and apparent 
permeability values reported in literature. 
 
parameters. Papp for propranolol found in the FTPC (2.5 ± 0.52·10
-5 cm/s) nicely falls 
within the range reported in literature and thus suggests that both assays deliver 
comparable results for highly permeable compounds and both system exhibit 
comparable hydro dynamical properties. For low permeability compounds such as 
fluorescein-Na, a comparable Papp (4.7 ± 0.57·10
-7 cm/s) suggests an intact monolayer 
throughout 210 min. This statement is furthermore compounded by TEER values still 
being above 350 Ω·cm2 and by microscopical observation of the monolayer. 
Consequently, apical and basolateral flow of 1.00 ml/min was found to be optimal for 
our purposes since this flow was still high enough to carry over the faster dissolution 
signal into the apical permeation site and maintained the barrier integrity of the Caco-2 
monolayer. 
The excipients for the formulation of the tablets have been chosen in order to 
minimize osmotic stress on the Caco-2 cell monolayer. Therefore, the fraction of soluble 
excipients was selected to be lower than 30 %. Considering the relative high volume in 
the dissolution modules, cells are highly unlikely to be negatively affected by osmotic 
stress due to dilution. Additionally, the excipients have been selected in order to prevent 
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filter clogging (e.g. no gel formation agents). Furthermore, all used excipients yet have 
not been reported to affect drug permeation through Caco-2 monolayers. 
 
2.4.2 Assessment of drug permeability and dissolution at different dosage strengths 
 
The 5 and 10 mg propranolol HCl immediate release tablets, as shown in Figure 
2.6, yielded a dissolution profile as expected for immediate release tablets. Dissolution 
profile of the 20 mg propranolol HCl immediate release tablet showed a minor shoulder 
at the beginning of the experiments (at about 10 min), whereas the dissolution profile of 
the 5 and 10 mg propranolol HCl can be seen as almost perfectly shaped peak. The 
shoulder of the 20 mg dosage form could be ascribed to the high content of 
propranolol HCl in the tablet with a ratio of 20 % (m/m) propranolol HCl, thus dissolution 
properties of the tablets or slowing down disintegration of the tablet. Dissolution profiles 
obtained using two 10 mg propranolol HCl tablets instead of one 20 mg tablet did not 
show such shoulder and thus support this hypothesis (data not shown). Additionally, 
the saturation solubility of propranolol is reported to be approximately 100,000 µg/ml 
[61] and this concentration has by far never been reached. Comparing the two profiles 
obtained from sampling port D and A (Figure 2.6), one can see that the peaks 
measured at sampling port A were flattened compared to those measured at D, and 
additionally, a time shift of about 10 min had occurred. Both phenomena, flattening and 
time shift, are unwanted but inevitable in a flow through system. Undesired convection 
and mixing processes in the tubes, the stream splitter in the FTPC and time for physical 
transport from D to A could be seen as causes for that. For that reason, minimizing 
these influences may be an issue for further optimization of the apparatus since all the 
factors are affecting the original dissolution signal. Nevertheless, it can be pointed out 
that the shape and the character of the peaks did not change significantly. The function 
of the stream splitter is of vital interest for the whole apparatus Therefore, linearity of the 
stream splitter connecting both modules and being responsible for providing a 
decreased stream to the permeation module was tested. As the stream splitter divided 
the incoming 6.5 ml/min stream into a 1.5 ml/min and a 5.0 ml stream, the ratio 
between mass inserted into the dissolution module and cumulative mass measured at 
A should be 1/6.5 = 0.1538. Linear regression of cumulative amounts at A versus the 
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mass of drug in the tablet (see Table 2.4) led to a slope of 0.154 +/-0.007 (R2 > 0.999) 
and  matches quite precisely the theoretical values, thus indicating high precision and 
high reproducibility of the stream splitter.  
 
 
Dosage 
strength 
(n=10) [mg] 
Amount 
appeared at A 
[mg] 
Amount 
permeated [µg] 
after 60 min  
Amount 
permeated [µg] 
after 120 min a 
Ratio [%] 
5 mg IR tablet 5.33 ± 0.21 0.68±0.03 1.98 ± 0.42 2.34 ± 0.47 0.343 ± 0.082 
10 mg IR tablet 9.70 ± 0.25 1.30 ± 0.02 3.77 ± 0.50 4.23 ± 0.45 0.325 ± 0.039 
20 mg IR tablet 19.23 ± 0.54 2.81 ± 0.22 6.82 ± 0.23 8.40 ± 0.32 0.292 ± 0.034 
 R2 0.9998 0.9998 <0.9999  
 Slope 0.1541 0.3462 0.4365  
10 mg ER tablet 
4% Eudragit® 
NE 30D 
 1.35 ± 0.06  4.55 ± 0.34 0.336 ± 0.040 
10 mg ER tablet 
8% Eudragit® 
NE 30D 
 1.16 ± 0.04  4.40 ± 0.28 0.378 ± 0.037 
 
Table 2.4. Synopsis of data for the IR and the ER tablets (mean ± stdev, n = 4-5). a for the extended 
release tablet, the amount appeared at the respective sampling port (A or B) after 180 min was taken into 
consideration. 
 
Granted that also the permeation part of the system works linear, the amount which 
permeated after 120 min and after 60 min through the Caco-2 monolayer should be 
directly proportional to the dosage strength of the inserted tablet. Therefore, the 
permeated amounts after 60 and 120  min were correlated with the dosage strength . 
As it can be seen in Table 2.4, the permeated amount after 60 and 120 min nicely 
follows the amount of drug inserted in the dissolution module, which is expected since 
permeation of propranolol as a passively transported compound [62] is linear. Linearity 
of both regressions are described by a R2 greater than 0.999 and indicate good 
reproducibility and high precision of both, the permeation and dissolution 
measurement. The ratio between the cumulative amount appeared at A at the end of 
the respective experiments and the final amount of propranolol HCl found in the 
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basolateral compartment are shown in Table 2.4. These ratios are consistent with data 
already published in literature, e. g. Miyazaki et al. [53] reported for the high permeable 
compound caffeine a ratio of 0.396 %.  
 
2.4.3 Assessment of drug permeability and dissolution at different release kinetics 
 
As mentioned before, one can detect in Figure 2.7, a flattening and broadening 
of the dissolution peaks throughout the passage of the apparatus. Again the shape of 
the peaks remained the same. Measuring permeation of prolonged release tablets 
raises the question for the maximum assay time. Small intestinal transit time is generally 
considered as 3.3 h [71] or is reported to range between 3.5 and 4.5 hours [43]. 
Viability of Caco-2 cells in KRB and in other HBSS-like buffers is most probably limited 
to approximately 5 to 7 hours, and consequently limitation in assay time might be 
irrelevant  
Considering the appearance of propranolol HCl in the basolateral compartment, 
a visible delay was found for the extended release tablets. After 180 min, however, 
permeated amount was for all different release kinetics fairly equal. For the permeation 
process in an open system, two variables can be considered as rate determining for 
permeation in this case. First, the concentration difference according to Fick´s first law 
– the driving force for diffusion - and second, the contact time of propranolol HCl with 
the Caco-2 cells – the probability which is given for propranolol to permeate. 
Considering the total permeated amount, prolongation of release from propranolol HCl 
tablets is affecting both variables controversially. For that reason, the final mass of the 
three extended release tablets in the basolateral compartment seemed to be rather 
equal as it can be seen in Table 2.4. As the retardation increased, slightly increasing 
ratios were found. Since retardation of propranolol HCl release was only moderate, the 
differences of the quotients were statistically not significant (one way ANOVA). Higher 
degrees of retardation will presumably lead to more profound effects on permeation. 
In order to compare the profiles of the extended release tablets, mean times for the 
different sampling ports were calculated according to Eq (3) to Eq (5). If MTD is plotted 
against MTA, linear regression leads to Eq (6) (graph not shown): 
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  MTA = 16.04 ± 0.60 min + 0.78 ± 0.015 · MTD  R2 > 0.999  Eq (6) 
 
The intercept of approximately 16 min can be regarded as time for drug release added 
the time needed for physical transport from the dissolution vessel to the apical 
compartment of the FTPC. The targeted value for the slope is 1 and is not matched 
exactly; mixing and convection appeared to affect that value. High linearity (R2 > 0.999) 
suggests high reproducibility for the transport throughout the apparatus. Figure 2.8 
plots both, MTD and MTA, versus MTB. Regression leads to Eq (6) and Eq (7): 
 
  MTB = 18.01 ± 3.50 + 0.85 ± 0.090 · MTD   R2 > 0.99   Eq (7) 
 
  MTB =  0.62  ± 6.28 + 1.08 ± 0.13  ·  MTA   R2 > 0.99   Eq (8) 
 
The intercept of approximately 18 min in Eq (7) can be attributed to the time of physical 
transport of the drug from the dissolution vessel to the apical compartment of the FTPC 
and subsequent permeation. The difference between the intercept of Eq (6) and Eq (7) 
of approximately 2 min can roughly be estimated as time of permeation. The slope of 
0.85 is close to the targeted value of 1; again, mixing and convection might have 
affected the signal. The intercept of Eq (8) was very small, which was expected. 
Physical transport can be considered as negligible, since, due to equal tubing, 
transport from the FTPC to both sampling ports happened within the same time. Here, 
the calculated slope matched precisely the targeted value of 1. For confirmation, mean 
time for permeation was calculated according to Eq (9): 
 
 mean time for permeation: MP = Papp · monolayer thickness  Eq (9) 
 
Assuming a Caco-2 monolayer height of approximately 20-30 µm [72] and a Papp of 
2.5 10-5 cm/s, MP can roughly be estimated as 80 to 120 s. This value apparently 
corresponds well with the intercept of Eq (8) and the difference of the intercepts of 
Eq (6) to Eq (7). In summary, it can be pointed out that using a mean time approach 
consistent and plausible explanation for the different concentration time profiles were 
found. 
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Figure 2.8. Mean times of the three differently retarded tablets assessed from sampling port B are plotted 
i) against mean times assessed from sampling port D (●) and ii) against mean time assessed from 
sampling port A (○). R2 < 0.99 for both regression lines. 
 
In contrast to previously published setup, the here described apparatus facilitates the 
use of complete oral dosage forms with physiologically relevant volumes and drug 
concentrations. Beyond that, the use of a commonly accepted and extensively 
described compendial dissolution device entails the advantage of comparability and 
reliability. A further advantage is obviously the installation of the stream splitter dividing 
the dissolution and permeation system into two hydrodynamically independent 
subunits. This facilitates, in comparison to previous setup, the application of pumps in 
the dissolution module as they are generally recommended for flow though dissolution 
cells. Thorough drug quantification at various sampling port facilitates a better tracing of 
drug in the apparatus. Nevertheless, the here described apparatus is lacking a unit 
mimicking the gastrointestinal pH gradient. Additionally, efforts for performing 
experiments have been increased.  
After all, it is worth to mention that is was not intended to mimic perfectly in-vivo 
dissolution and permeation conditions. Although, it was possible to simulate the 
estimated volumes of liquid accessible for dissolution and intestinal concentrations, it is 
up to now not possible to simulate the area accessible for permeation and present in-
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vivo, which would be deductive for permeation when mimicking the volumes in the 
gastrointestinal tract. It remains, however, unclear whether results from such perfect in-
vivo apparatus will achieve adequate results when comparing to the financial efforts 
which have to be made therefore.  
Summarizing these experimental results, one can conclude that our new 
apparatus was able to monitor permeation through a Caco-2 monolayer of drugs 
formulated as a solid dosage form. The apparatus showed linear behaviour for 
increasing dosage strengths of propranolol HCl immediate release tablets and also 
linear behaviour in terms of retardation of release. 
 
 
2.5 Conclusion 
 
A successful installation of a promising novel apparatus for the assessment of 
intestinal permeability of drugs formulated as solid oral dosage forms was realized by 
combining a flow through Caco-2 permeation cell with a compendial flow though 
dissolution cell (USP apparatus 4). This combination of established, but so far only 
separately used research tools yields plausible data, not only for immediate but also for 
extended release tablets of the BCS class I compound propranolol HCl. Problems 
arising from applying compendial flow through dissolution devices were adequately 
solved by a stream splitter. The above shown data provides the basis for more 
advanced studies on the influence of dosage form, excipients and other factors on the 
permeation as well as the dissolution process. 
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3 Computational modeling of the prototype 
 
 
In order to improve the understanding of flow dynamics, mass transport and 
permeation processes, concentration time profiles at the various sampling ports 
have been modeled computationally. The hereby developed program is able to 
simulate the behavior of drug/solid dosage forms in the apparatus and is a tool for 
estimating dissolution and permeability in silico for the here described apparatus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work for this section has been performed in collaboration with the Center of Bioinformatics, Saarland 
University and is part of the bachelor thesis of Thomas Schackmann. Dr. Dirk Neumann was co-
supervisor of this work at the Center of Bioinformatics. 
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3.1 Introduction 
 
 Computational methods are evolving more and more to valuable tools in 
pharmaceutical sciences. In silico modeling of experiments enables the researcher to 
improve experimental planning and thus to decrease the number of failed experiments. 
Furthermore, computational modeling allows optimization of experimental conditions 
with low application of lab resources. 
For the here described setup assessing permeability of solid dosage forms, a modeling 
of the apparatus would specifically facilitate following features: i) detect influences of 
tubing/hydrodynamical properties on dissolution and permeation signals and hence 
improve and speed up rational optimization of these parameters, ii) objective 
classification of drugs into categories such as high and low soluble or high and low 
permeable, and iii) check plausibility of experimental results. 
For the computational simulation, a compartmental model has been defined as shown 
in Figure 3.1. Drug release and flow rate in the flow through dissolution cell determine 
the velocity of drug leaving this compartment towards the stream splitter. In the stream 
splitter, drug molecules have either the possibility to be led to the waster or to be led to 
the flow through permeation cell (FTPC), whereas the ratio between the flow rates in the 
flow through dissolution cell and the flow through permeation cell determines this 
probability. As the drug enters the FTPC, the drug may permeate into the basolateral 
compartment of the FTPC or if not may be led to the waste. 
 
 
Figure 3.1. Compartmental basic model for the simulation of the apparatus for permeability assessment 
of solid oral dosage forms. 
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3.2 Material and methods 
 
In the following, several putative approaches for simulating mass transport and 
concentrations at the various sampling ports are described. 
3.2.1 Basic model of a compartment 
 
A putative approach to model mass transport is to divide the apparatus into 
several compartments and to monitor the concentration in those compartments. A 
compartment describes a balanced region in which system parameters are constant or 
change only insignificantly. The volume flows are calculated by means of mass 
balance, density distribution and the actual flow rates. Consequently, a compartment is 
characterized by its volume V and the number of molecules/particles inside the 
compartment resulting in the concentration of molecules/particles in the compartment 
(Figure 3.2).  
 
Figure 3.2. Basic model of a compartment. Explanation is in the text body. 
 
Flow rate into the compartment (Fin), the amount of molecules/particles entering the 
compartment (nin), and accordingly the concentration of molecules/particles entering 
the compartment (cin) and their contrariwise parameters Fout, nout, and cout are 
characterizing the compartment. 
 
3.2.2 Random walk 
 
In order to mimic the broadening of peaks in the apparatus, the random walk 
may be a valuable tool. The basis for the random walk can be seen in the area of the 
Monte Carlo simulation. The one dimensional random walk is considered to be a 
Bernoulli process; more exactly, a series of independent Bernoulli experiments leading 
to a binomial distribution. A particle allowed to move accordingly in one dimension has 
the probability to do one step forward of p, whilst the probability to do one step back is 
q = 1-p. When q = 1/2 = p, no predominant direction is given. Consequently, the 
__________________________________________________________________________________________ 
Computational modeling of the prototype 
3-46 
probability that a particle has made after n steps the way X can be calculated according 
to Eq (10).  
 
 P(X)=⎝⎜
⎛
⎠⎟
⎞n
k  p
k qn-k       Eq (10) 
 
As a consequence, when a particle is allowed to diffuse freely, the mean square 
distance between the place of origin of the particle and the actual localization is 
growing proportionally to the time (compare Higuchi square root law for diffusional 
processes). Particles obeying the rules of a two dimensional random walk are allowed 
to change their location to a new field once per time step as indicated in Figure 3.3. 
 
 
Figure 3.3. Degrees of freedom for a particle in a random walk 
 
Depending on following conditions, the random walk of a particle is obeying the 
following rules.  
1.) If the place to be occupied with the next step is free, the move will be allowed 
and the particle is placed on the desired position. 
2.) If the place to be occupied with the next step is already occupied, the move 
will not be allowed. 
3.) If a particle moves to a field named as "leak site", the particle is removed from 
the matrix. Consequently, the particle is allowed to participate the subsequent 
transport or other processes.  
The above addressed type of random walk is applied for particles exhibiting a certain 
size and thus demanding a certain unoccupied place to move to. For the modeling of 
diffusional processes in diluted solutions, case 2.) can be neglected. Case 3 has been 
implemented in order to simulate the outflow of substance from a compartment, in 
which the apparatus is segmented. A visual explanation of the random walk is illustrated 
in Figure 3.4. The left depiction shows the start configuration at time zero. The leak site 
is indicated by the grey fields. The configuration after n steps is shown on the left side. 
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Two particles have already left the matrix, one particle will be removed from the matrix 
within the next step, and six particles will remain in the matrix at the next step.  
 
 
Figure 3.4. Illustration of a two dimensional random walk. Explanation is given in the text body. 
 
 
3.2.3 Dynamics of flow 
 
A suitable model to describe the behavior of a liquid streaming through a 
cylindrical tube can be illustrated as follows: 
A liquid with a dynamic viscosity η is seeped through tubing with the radius R by a 
pressure gradient ∆p. The cylinder of liquid with radius r and length l experiences at its 
superficies the frictional force FR as described by Eq (11), 
 
 FR = 2π r l η dvdr       Eq (11) 
 
and at its top surface the pressure force FP (Eq (12)) 
 
 FP = π r2(p1-p2 )       Eq (12) 
 
In the steady state, pressure force and frictional force are equalizing each other and 
from FP = FR follows: 
 
 2π r l η dvdr = π r2(p1-p2 ) ‹ 
dv
dr = 
π r2(p1-p2 )
2π r l η  ‹ 
dv
dr = 
p1-p2
2η l Ωr Eq (13) 
 
resulting in a parabolic flow profile according to Figure 3.5. 
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Figure 3.5. Parabolic flow profile through a cylindrical tube.  
 
 v=vo-
p1-p2
4η l  r2,  if   v0=
p1-p2
4η l  R2      Eq (14) 
Through the hollow cylinder between r and r + dr, a volume flow dV is streaming 
 
 dV = 2π r v(r)dv       Eq (15) 
 
and through the complete tubing 
 
 dV =⌡⌠
0
R
 2π r v(r)dr =π (p2-p1)8η l  R4     Eq (16) 
 
, which is known as the law of Hagen-Poiseuille or law of Ohm for voluminal laminar 
stationary flow of incompressible uniform viscous liquids (Newtonian liquids). 
Consequently, the median fluid velocity along the length of the tube v can be calculated 
as 
 
 v = Vπ R2 = 
1
2 v0       Eq (17) 
 
Since neither ∆p nor η are know parameters of the apparatus, the above described 
equation has to be converted as follows summarizing both parameters to a simplifying 
constant c, which can be calculated using the known parameters R, l, and V: 
 
 V = π ∆p8η l  R4 ‹ V = 
∆p
η  Ω 
π R4
8l  ‹ 
∆p
η  = 
V8l
π R4 = c   Eq (18) 
 
If a particle is placed in such cylindrical tubing, one can calculate its velocity vi by 
means of the distance ri of the particle from the central point of the cylindrical tubing. 
 
 vi = vo - cΩri
2 with c = c4l = 
∆p
4η l = 
2V
π R4    Eq (19) 
In the following, the dynamic viscosity at 20 °C is considered to be 0.001 Pa/s. 
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3.2.4 Generation of the dissolution profile 
 
A mathematical function displaying the input of mass/particles into the apparatus 
is needed. Drug dissolution from solid dosage forms can be described by kinetic 
models in which the dissolved amount of drug (Q) is a function of the test time, t or 
Q=f(t). Some analytical definitions of the Q(t) function are commonly used, such as 
zero order, first order, Hixson-Crowell, Weibull, Higuchi, Baker-Lonsdale, Korsmeyer-
Peppas and Hopfenberg models among others. For a comprehensive review on this 
topic please refer to [73]. Two models are described here. 
 
3.2.4.1 Higuchi model 
Higuchi developed in 1961 [74] a model to describe the release from semisolid 
and solid dosage forms. When assuming a planar and homogenous matrix releasing a 
drug, Eq (20) can be used to describe the release. 
 
 ft = Q = D(2c-cs )cst       Eq (20) 
 
, whereas Q is the amount of drug released at time t, c is the initial concentration, cs is 
the saturation concentration in the release media, and D displays the diffusions 
constant according to Einstein of the drug molecule in the matrix. For spherical 
matrices, Higuchi described drug release as shown in Eq (21). 
 
 ft = Q = KHΩt
1
2        Eq (21) 
 
, while KH is the considered as the Higuchi dissolution constant. 
3.2.4.2 Weibull model 
The empirical exponential equation described by Waloddi Weibull (1887-1979) Eq (22) 
can be applied to almost all dissolution curves.  
 
 
Mt
M¶
 = M¶ Ω [ 1 - e
 -aΩ(t-Ti)
 b]      Eq (22) 
 
, whereas Mt is the cumulative amount of drug in solution at time t. Ti describes the 
delay of release and this case considered to be zero. For b = 1, an exponential shaped 
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curve is yielded; for b > 1, a sigmoid shaped curve. For a more detailed study on this 
particular topic, the author refers to Costa et al. [73].  
 
3.2.4.3 Applying the Weibull function to simulate drug release 
The Weibull function was used to calculate the released amount of drug per time 
step. Prior to the modeling, the cumulative concentration time plots at sampling port D 
of the 5, 10, and 20 mg immediate release tablets were compared to the Weibull 
function. If a proper correlation was achieved, an appropriate description of the drug 
release in the flow through dissolution cell would be highly likely. Figure 3.6 plots both 
experimental and fitted data. Table 3.1 summarized the respective parameters. 
 
Figure 3.6. Cumulative amount of propranolol HCl detected at sampling port D for the 5 mg (●), 10 mg 
(○), and the 20 mg (▼) immediate release tablet. Weibull function is indicated by dotted line and thin X. 
Fitting parameters are summarized in Table 3.1. 
 
The low RMSD and high R2 in Table 3.1 as well as the obvious good correlation in 
Figure 3.6 suggests that the Weibull function can be used in this case for modeling the 
drug release in the flow through dissolution cell. 
 
Table 3.1. Parameters obtained from non linear fitting of the cumulative amount of propranolol HCl 
detected at sampling port D for the 5 mg, 10 mg, and the 20 mg immediate release tablet against a 
Weibull function (Eq. (22)) 
Parameter: M¶ a b RMSD R2 
  5 mg 4.45 0.0132 1.501 0.156 0.991 
10 mg 8.84 0.0101 1.570 0.307 0.993 
20 mg 18.78 0.00124 1.936 0.342 0.935 
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3.2.5 Positioning of the particles in the tubing 
 
When a particle is allowed to leave a compartment into a tubing, they are 
randomly positioned on various sectors as indicated in Figure 3.7. In the next modeling 
step, particles closer located to the center are subjected to a faster flow than particles 
which are more remote from the center (law of Hagen-Poiseuille). As a consequence, 
this model is used to simulate peak broadening and flattening throughout the passage 
of the apparatus. 
 
Figure 3.7. Schematical depiction of the particle positioning on the various sectors of a tubing. Black dot 
indicate randomly placed particles. 
 
3.2.6 Optimizing the computational model 
 
In order to optimize and to calibrate the computational model, a solution with a 
known volume and concentration was inserted into the flow through dissolution cell and 
concentration were assessed at sampling ports D and A. Concentration of the solution 
was 20 µg/ml, volume was 5 ml, so that in total 100 µg propranolol HCl were inserted 
into the apparatus. The concentration time trends are as shown in Figure 3.8. At 
sampling port D, 98.53 % of the inserted amount of drug was found, i.e. 98.53 µg. After 
60 min, 14.01 % of the initial amount was detected at sampling port A, which is close to 
the targeted value of 15.38 % when assuming a split ratio of 1 ml/6.5 ml = 15.38 %. To 
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conclude, a valid data set is with a known dissolution, namely no dissolution since a 
solution was inserted, was found facilitating proper optimization. 
 
Figure 3.8. Concentration time trends for 5 ml of 20 µg/ml propranolol HCl solution in KRB 7.4 for 
sampling port D (left plot) and sampling port A (right plot). 
 
As one can see in Figure 3.9, data obtained from the simulation (○) fits nicely to the 
experimental values (●). Although some differences can be observed, especially 
around the peak concentrations and at the increasing part of the peak, the simulated 
data describes the experiment sufficiently. By applying this approach, validity and 
exactness of the model can be evaluated. 
 
Figure 3.9. Both experimental (○) and simulated (●) data for the 20 µg/ml solution is plotted.  
 
3.2.7 Error function 
 
In order to facilitate comparison of modeled concentrations with measured 
concentrations at any time point, an error function had to be found. The optimal error 
function for the 5, 10, and 20 mg immediate release tablet was determined as Eq. (23). 
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f(x) = a Ω 1
 1+e-
x-x0+b/2
c
 Ω [1- 1
1+e-
x- x0-b/2
d
 ]    Eq (23) 
 
In order to estimate the quality of correlation, the root mean square deviation has been 
calculated according to Eq. (24) 
 
RMSD = 1N ∑
i=1
 i=N
 ei
2       Eq (24) 
 
, whereas N is the number of compared pairs and ei
2 is the squared error of a pair. 
Correlation coefficient R was calculated according to Bravais-Pearson and squared:  
 
R = 
1
n ∑
i=1
n
(xi-x)(yi-y)
 1n ∑
i=1
n
(xi-x)
2 Ω 1n ∑
i=1
n
(yi-y)
2 
     Eq (25) 
 
whereas  x = 1n ∑
i=1
n
xi  and .  y = 
1
n ∑
i=1
n
yi . 
 
Figure 3.10. Error function (○) and experimental data (●) are plotted exemplarily against time for the 10 
mg immediate release tablet for sampling port D (left plot) and sampling port A (right plot). 
 
Figure 3.10 shows exemplarily experimental data and data obtained from Eq (23) with 
parameters as shown in Table 3.2. In summary, an appropriate equation with sufficient 
accuracy indicated by low root mean square deviation (RMSD) was found. 
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Table 3.2. Summary of the parameters for the error function for the sampling port D and A using Eq (22). 
Route mean square deviation (RMSD) is given in the last column. 
 100 µg solution 5 mg IR tablet 10 mg IR tablet 20 mg IR tablet 
 D A D A D A D A 
a 13.91 6.56 131.97 231.57 94.24 447.58 9.46 875.22 
b 1.44 96.35 - 5.03 - 20.13 10.46 - 24.36 - 28.07 - 38.34 
c 1.15 x 10-8 2.52 x 10-3 0.52 1.59 0.98 1.50 0.41 3.77 
d 1.83 185.81 10.24 13.23 7.71 1.498 16.63 20.90 
x0 2.72 348.18 1.56 3.70 x 10-4 11.01 2.01 x 10-4 -8.84 x 10-11 3.98 x 10-10 
RMSD -- -- 6.83 2.02 2.26 1.45 1.07 0.82 
 
3.2.8 Modeling the flow through dissolution cell 
 
The flow through cell has been modeled as follows: It consists of one 
compartment with an exit to a tubing compartment. Within the compartment, a certain 
number of particles are located and a certain number is allowed to leave the 
compartment into the tubing compartment per time step. Here, a particle is randomly 
placed on a sector of the tubing as shown in Figure 3.6 (p. 3-51). For the simulation of 
dissolution, a Weibull function as addressed in 3.2.4.2 (p 3-49) displayed the best 
choice and was applied. For future application, dissolution function can be changed in 
respect to the releasing kinetic of the dosage form. 
 
3.2.9 Modeling the stream splitter 
 
In the simulation, the stream splitter comprises a single compartment and 
deviates in its properties from the basic compartment model as stated in 3.2.1 (p. 3-45) 
as follows: The compartment possesses two outlets (Fwaste and Fapical). In the 
experiments, the 6.5 ml/min stream from the dissolution cell is divided into a 5.5 ml/min 
stream for the waste and a 1.0 ml/min stream for the apical compartment. For 
simulation, a random number p ∈ [0; 6.5] is determined for each particle currently 
located in the stream splitter and for p ≤ 1, the particle is allowed to proceed to the 
permeation cell. For r 1 < p ≤ 6.5, the particle is removed from the simulation. The 
stream splitter is moreover simulated as space and the movement of particle within this 
space is modeled by means of a random walk (section 3.2.2, p. 3-45) 
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3.3 Results and discussion 
 
Hitherto, simulated concentrations time profiles will be exemplarily shown for the 
20 mg immediate release propranolol HCl tablet. Since this project of modeling the 
prototype is still ongoing, data shown is considered to be preliminary.  
In Figure 3.11, simulated data for sampling port D is compared to experimental 
data by plotting both in one graph. The simulated data describes properly the time of 
the maximum concentration, whereas the peak height is in the simulation with 80 µg/ml 
too low. However, taking the standard deviation of the experimental data into account, 
the simulation only slightly failed. The rise to the peak and the time shift is predicted 
correctly. The shoulder in the experimental data is not predicted, since the shoulder can 
be regarded as an experimental artifact as already stated in 2.4.2 (p 2-36 and ff.) and  
 
Figure 3.11. Experimental data from sampling port D of a 20 mg immediate release tablet (○) and 
simulated data (●, dashed line) is plotted against time.  
 
prediction by a computational model is highly not expected. The concentration 
decrease at sampling port D is simulated to be slightly slower; however, simulated data 
keeps always close to the experimental data with respect to the error bars. The terminal 
part of both concentrations time trends are rather similar. In order to provide objective 
comparison between the calculated and the experimental data set, Figure 3.12 plots 
them against each other. Non linear regression led to the following equation: (mean ± 
standard error) 
c sim data = (0.9296 ± 0.0550) · cexp data + (0.2460 ± 2.5097) ; R
2 = 0.96 
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Figure 3.12. Simulated data is plotted pairwisely versus experimental data for sampling port D. 
Correlation coefficient of the linear regression line was calculated as 0.96. Dotted lines indicate the 99 % 
confidence interval. 
 
RMSD was calculated as 9.167. Slope of the regression line is close to one. Apparently, 
data points scatter randomly around the regression and no systematic error is visible 
suggesting that the simulation is able to calculate the concentration time trends for 
sampling port D for the 20 mg immediate release tablet correctly. 
 
Figure 3.13. Experimental data from sampling port A of a 20 mg immediate release tablet (○) and 
simulated data (●, dashed line) is plotted against time. 
 
The calculation of concentration time trends at sampling port A is considered to 
be more difficult. Not only drug release from the dosage form and the escape of drug 
out of the flow through dissolution cell has to taken into consideration, but also the 
stream splitter and peak broadening and flattening as a function of tubing length and 
diameter are affecting the shape of the peak. Figure 3.13 plots experimental and 
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calculated concentration in one plot. It is clearly visible that the simulated 
concentrations show some scattering between 30 to 60 min. This, however, is attributed 
to the lack of a smoothing algorithm in the simulation. This may be a subject of 
optimization in the future. Nevertheless, the shape of the peak is described correctly, 
peak concentrations are both at the same time and at the same concentration of 
approximately 80 µg/ml.  
Figure 3.14 plots both data sets as pairs against each other. Non linear regression led 
to the following equation: 
c sim data = (1.1478 ± 0.0671) · cexp data + (1.7207 ± 2.9532) ; R
2 = 0.97 
 
Figure 3.14. Simulated data is plotted pairwisely versus experimental data for sampling port A. 
Correlation coefficient of the linear regression line was calculated as 0.97. Dotted lines indicate the 99 % 
confidence interval. 
 
RMSD was calculated as 11.753 and is slightly higher than for sampling port D. Also, 
slope of the regression is not that close than for sampling port D. Nevertheless, the 
data points appear to scatter randomly around the regression line indicating the lack of 
a systematic error. 
Data for sampling port B representing the permeation process is yet not 
available. However, after having made the important milestone with the successful 
calculation of the concentration time profile at sampling port D and A, simulating 
sampling port B will be straightforward since no convectional processes have to be 
considered. It is planned to give a in silico particle located in the apical compartment of 
the flow through permeation cell a probability to enter the basolateral compartment, i.e. 
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to permeate, or the leave the FTPC into the waste, while the probability will be 
calculated according to the Caco-2 permeability of the compound. 
3.4 Conclusion 
 
From the above shown data, one can conclude that a promising first step for a 
computational modeling of the dissolution - permeation prototype has been done. The 
concentration time trends at two sampling ports have been calculated correctly and 
also peak broadening and flattening from sampling port D to A have been calculated 
correctly.  
The next step of this project will be to implement a permeation step into the 
simulator and to test weather the simulator is predicting the concentration time trends 
and permeation of the propranolol HCl extended release tablets. 
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4 Automation 
 
 
One major conclusion of the proof of concept study in chapter 2 was to automate 
sampling and quantification at the various sampling ports in order to increase 
throughput and to decrease manpower consumption. Sequential injection 
technique was found to be an optimal tool because of its simplicity, versatility, and 
robustness.  
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this section have been published in  
 
Motz SA, Klimundová J, Schäfer U, Balbach S, Eichinger T, Solich P, Lehr CM. Automated measurement 
of dissolution and permeation of propranolol HCl tablets using sequential injection analysis, Analytica 
Chimica Acta, Acta 581 (2007) pp. 174–180, [75]. 
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4.1 Introduction 
 
Several apparatus for simultaneous measurement of dissolution and permeation 
through Caco-2 have been established in the past years [39, 50, 52-55], and 
auspicious results were obtained. Combining two in vitro- methods to forecast behavior 
of solid oral dosage forms when administered in vivo appears to be a promising tool to 
obtain more vital information of the in vivo- performance compared to deploying both 
assays separately. Generally speaking, these apparatuses can be divided into two 
classes. Ginski et al. [76] and Kataoka et al. [56] reported on a closed dissolution and 
permeation system, either using the USP apparatus 2 or a specially designed 
dissolution vessel. In contrast, Miyazaki et al. [52-55] and our group are using open 
systems for dissolution and permeation assessment. Whereas Miyazaki et al. is using 
glass or plastic vessels of different sizes, our group applies the USP apparatus 4 for 
dissolution measurement. However, simultaneous analysis of dissolution and 
permeation remains tedious and labor consumptive; not only the use of viable cells but 
also manual sampling and analysis with HPLC definitely limits the throughput. HPLC 
based quantification can be considered as time consumptive and also as money 
consumptive, since expensive mobile phase, vials and further equipment have to be 
used. In addition, organic solvents wastage bears issues concerning environmental 
pollution. In most cases, however, selectivity provided by HPLC is not necessary if only 
one active pharmaceutical ingredient (API) is used and if sensitive and/or selective UV 
or fluorimetric detection are possible. 
Sequential injection analysis (SIA) and its predecessor flow injection analysis 
(FIA), which has been developed in 1975 [77], have been continuously applied in 
pharmaceutical sciences and further improved [78-80]. SIA facilitates fast and 
reproducible on-line sample handling such as sample aspiration, sample dilution, solid 
phase extraction and many other applications [81]. Additionally, SIA permits - in 
combination with fluorescence or UV-detectors - fast and reliable quantification of many 
pharmaceutically applied compounds [78, 79]. Beyond that, SIA is described to be a 
flexible, robust and a highly versatile tool for automating sampling and sample treating. 
For these reasons, sequential injection analysis appears to be an ideal solution for our 
purposes, especially when high sampling frequency and rapid online quantification is of 
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vital interest. Several groups reported to employ SIA for automating dissolution systems 
using both fluorimetric [82-84] and UV [85-87] detection. The detection limit of 
fluorimetric quantification was comparable to quantification limits provided by HPLC 
based methods (30 ng ml-1 for ergotamine tartrate [83] and 50 ng ml-1 for acetylsalicylic 
acid [82]).  
Test substance for combined measurement of dissolution and permeation was 
propranolol HCl. It was chosen because of its favorable biopharmaceutical properties 
exhibiting high solubility and high permeability [59] and is therefore assigned to the 
biopharmaceutical classification system class 1 [46]. Beyond that, quantification of 
propranolol HCl is easily accessible using either HPLC method with UV detection or 
fluorescence detection. Taking into account that for combined measurement of 
dissolution and permeation relatively high concentrations in the dissolution part and 
relatively low concentration in the permeation part have to be measured, fluorimetric 
detection would be an appropriate way to quantify in a SIA based system dissolved and 
permeated propranolol HCl in the matrix Krebs-Ringer Buffer. 
Not only the usually rather time consumptive manual sampling procedure was 
subjected to optimization, but also lag time and dead volumes were found to be still 
rather large in the apparatus described previously in Section 0. In order to minimize 
those issues, inner diameters of all tubing were chosen to be as minimal as possible. In 
addition, the volume of the acceptor compartment was decreased. Changes related to 
these modifications will be discussed subsequently. 
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4.2 Materials and Methods 
 
4.2.1 Methods 
 
Cell culture conditions were the same as described in 2.2.2. 10 mg immediate 
release test tablets were as described in 2.2.4. KRB was prepared according to 2.2.5. 
4.2.2 SIA system 
 
The SIA system consisted of the FIAlab 3500 (FIAlab instruments, WA, USA) 
implemented with a 2.5 ml piston pump, a peristaltic pump and an eight port 
multiposition valve. Standards were aspirated by means of an autosampler (Cetac 
ASX 260, NE, USA). Fluorimetric detection was performed with the FIAlab fluorescence 
detector PMT-FL. Integration time was set to 100 msec, scan rate was adjusted to 
2.0 Hz. An UV light source was purchased from Mikropack (type D-2000, Ostfildern, 
GE), and the light source was linked with the fluorescence detector with a fiber optic 
cable. An excitation filter (λexc = 260 nm, 10 nm full width half maximum, Andover 
Corporation, NH, USA) and no emission filter was used. Software was FIAlab for 
Windows® version 5.9.192. The program codes for the respective sampling ports are 
given in section 8.3.1 (main), 8.3.2 (D), 8.3.3 (A), and 8.3.4 (B) (pages 8-111 - 8-114). 
The configuration of the autosampler for the aspiration of standard solution from the 
standard tray was as given in Table 8.1. 
 
4.2.3 The automated apparatus for combined dissolution and permeation 
measurement 
 
The automated apparatus is schematically depicted in Figure 4.1, and a 
photograph is shown in Figure 4.2. The apparatus for combined measurement of 
dissolution and permeation can be divided into two modules: on the left the dissolution 
module with the flow through dissolution cell (USP apparatus 4, Sotax CE1, Sotax, 
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Lörrach, GE) and on the lower right side the permeation module with the flow through 
permeation cell, whereas both modules are connected by 
 
 
Figure 4.1. Schematic depiction of the automated apparatus for simultaneous measurement of 
dissolution and permeation. Sampling ports are indicated with capital letter, D for Dissolution, A for Apical 
and B for Basolateral. The multipositional valve and its port assignment was as follows. Port 1 was 
connected with the waste; port 2 with the autosampler for aspirating the standards solutions; port 3 was 
connected to the KRB supply for replenishing the volumes taken from the basolateral compartment. Port 
8 was connected to the fluorescence detector PMT-FL and ports 4, 5 and 6 are assigned to sampling 
ports B, A and D, respectively. 
 
means of a stream splitter providing appropriate low flow rates for the permeation 
module. The permeation module can be subdivided into two compartments: the open 
apical and the closed, circulating basolateral compartment, which comprises a stirred 
reservoir with a volume of 1.0 ml KRB and a measurement loop to the multipositional 
valve. Flow rate in the dissolution module was adjusted to 6.5 ml min-1 and to 
1.0 ml min-1 in the permeation module, respectively. Three points of sampling within the 
apparatus are indicated in Figure 4.1 with the capital letters D, A and B. Samples taken 
at sampling port D, directly after the flow through dissolution cell, are providing the 
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original dissolution signal. Concentrations at sampling port A, located at the apical part 
of the permeation module, exhibit the concentration in contact with the apical side of 
the Caco-2 monolayer. Concentrations measured at sampling port B allow the 
calculation of the amount permeated to the basolateral side of the Caco-2 monolayer 
(volume of the complete basolateral module 5.25 ml).  
 
 
Figure 4.2. Photograph of the automated setup. The SIA devices are placed on the right side, the water 
bath in the middle, and the controlling computer on the left side. 
 
The interface between the apparatus for combined dissolution/permeation 
apparatus measurement and the SIA system was as follows. At sampling port D and A, 
a tubing was used to directly connect the stream containing the dissolved drug with the 
multiposition valve. Volumes of the connecting tubing were 15 µl for D and 60 µl for A. 
In order to assure that correct concentrations were assessed, this connection was 
washed prior to each real measurement at sampling port D by aspirating 50 µl, and at 
sampling port A by aspirating 100 µl, respectively. Since the aspirated volumes 
compared to the flow rate at D (6.5 ml·min-1) are sufficiently low, no replenishment of the 
withdrawn sample was necessary. Also, at sampling port A, no replenishment was 
required since the stream is subsequently going to waste. The basolateral vessel 
posing the reservoir for the closed basolateral compartment was connected to the 
multiposition valve by means of a measurement circuit driven by the peristaltic pump of 
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the FIAlab 3500 system (flow = 0.9 ml·min-1). The dead volume of the connection 
between the measurement circuit and the multipositional valve was approximately 6 µl. 
Prior to aspiration of the real sample, 25 µl were aspirated in order to wash the T-
connector and were subsequently discarded. Post washing, 50 µl were aspirated for the 
fluorimetric analysis, and afterwards 75 µl of KRB were dispensed back into the 
measurement circuit. 
All tubing of the apparatus for combined measurement of dissolution and 
permeation and the SIA system were made of Teflon® to minimize adsorption; inner 
diameter of tubing in the dissolution module was 1.55 mm and 1.0 mm in the 
permeation module (Upchurch, WA, USA). Connection tubing to the multipositional 
valve had an inner diameter of 0.50 mm. The flow through dissolution cell was 
equipped with filters (type GF/D, Whatman International Ltd, Maidstone, UK) preventing 
undissolved drug and excipients from leaving the dissolution module. The flow through 
permeation cell was the same as described in section 1. The basolateral reservoir 
vessel was made of Polyetheretherketone (PEEK) (for details see Figure 8.6). The 
basolateral vessel was magnetically stirred (MINI 07, H+P, Oberschleißheim, GE). Prior 
to each experiment, all media were properly degassed by stirring 10 minutes under 
reduced air pressure. Before inserting in the apparatus, Caco-2 cells were washed 
twice with KRB and were allowed to equilibrate for at least 30 min in KRB at 37 °C. 
Then, TEER was measured and the Transwell® with a cell monolayer exceeding 
350 Ω·cm2 was inserted into the flow through permeation cell. Subsequently, the flow 
was adjusted to 1.0 ml·min-1 and cells were equilibrated for another 10 min before the 
experiment was started.  
Cumulative amount appeared at sampling port D and A has been calculated from the 
measured concentrations using Eq (26), which is derived from the trapezoidal rule: 
 
cumulative amount  = ∑
i=1
n-1
[
c(ti+1)+cti
2 Ω(ti+1-ti)]ΩFLOW   Eq (26) 
 
whereas c(t) is the concentration [µg ml-1] measured at time t [min] and c(ti+1) is the 
concentration measured at time ti+1. FLOW designates the flow rate [ml·min-1] in the 
respective module. 
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As the apparent permeability (Papp) is generally defined as flux over donor 
concentration, apparent permeability was calculated from the concentrations assessed 
at sampling port A and at B. Flux was estimated by interpolation using Eq (27). 
 
Flux at measurement point n: Fluxn = 
massn+1-massn-1
tn+1-tn-1
   Eq (27) 
 
Massn+1 is the mass permeated at measurement point n+1 and tn+1 is the time of the 
measurement point n+1. Massn-1 is the mass of the measurement before n, t is the time 
of the measurement point before n. The apical concentration at the respective time 
points were calculated using linear regression between two measurement points at A. 
 
4.3 Results and discussion 
 
4.3.1 Calibration 
 
Signal of native fluorescence of propranolol HCl was sufficiently strong for direct 
detection in the matrix KRB. Experiments with placebo tablets (the API propranolol HCl 
was replaced by lactose) led to signals comparable to those obtained from blank KRB, 
thus indicating that no interference of excipients with the analysis occurred. Standards 
were provided by aspiration from the autosampler, and peak height was correlated with 
standard concentrations. Flow rate of the analyte through in the PMT-FL was found to 
be ideal in terms of reproducibility and signal height at 50 µl s-1.  Since concentrations 
at sampling ports D, A and B differ strongly, different aspiration volumes were found to 
be optimal. Sampling port D and A exhibiting sampling ports with the highest 
concentration had an aspiration volume of 25 µl; however, sample aspiration volume at 
port B, where only low concentration are expected, was increased to 50 µl to assure 
sufficient sensitivity at low concentrations. The lower aspiration volume was shown to 
yield lower fluorescent signals combined with an increased linear part of the regression 
line. Consequently, higher aspiration volumes caused higher fluorescent signals and 
led to earlier non linear behavior. Nevertheless, it was not feasible by decreasing the  
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Figure 4.3. First order calibration of propranolol with fluorescence detection using the PMT-FL. The 
smaller graph shows the regression for the lower standards. 
 
aspiration volume to 25 µl to fit the calibration curve to a straight line as it can straight 
line as it can be seen in Figure 4.3, and thus calibration for sampling port D and A was 
performed with an first order polynomial equation. For 50 µl injection, calibration was 
performed with five standard solutions and for 25 µl injection with seven standards. 
Standard concentration for 50 µl injection were 0.05, 0.2, 0.4, 2.0, 4.0 µg ml-1 of 
propranolol HCl. Standards concentrations for 25 µl injection were 0.2, 0.4, 2.0, 4.0, 20, 
40, 80 µg ml-1 of propranolol HCl. All standards were measured in sextuple. Prior to 
regression, blank values obtained injecting KRB were subtracted. Relative standard 
deviation for the 50 µl injection at the lowest standard was 2.35 % (n = 6) and at the 
highest standard 1.63 % (n = 6). Linear regression led to the following equation: 
y = 4246.8 · c – 44.9 (y = fluorescence signal, c = concentration [µg ml-1], R2 > 0.999). 
Limit of quantification was calculated as 0.04 µg ml-1 (10σ); limit of detection   
0.02 µg ml-1 (3σ). Relative standard deviation at the lowest standard concentration for 
25 µl injection was 2.82 % (n = 6) and for the highest standard concentration 3.09 % 
(n = 6). Regression led to a first order polynomial equation (see Figure 4.3):                      
y = - 6.55 · c2 + 2669.1 · c – 18.7 (y = fluorescence signal, c = concentration [µg ml-1], 
R2 > 0.9999). The values for quantification and detection limit are consistent with values 
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found for comparable substances in literature [82, 83]. In conclusion, it can be pointed 
out that an accurate and sensitive quantification method for propranolol HCl was found 
and no interference with excipients occurred. 
 
4.3.2 Automated measurement of dissolution and permeation 
 
Sampling and analysis were performed alternating at sampling port D and A, 
intermitted by a measurement at sampling port B after every third loop of measurement 
at D and A. Sampling together with quantification took 0.7 min at sampling port D, 
0.9 min at A and 1.3 min at B. Time for sampling at port B lasted longer because of the 
time needed for replenishing KRB. Sampling frequency of approximately 60 h-1 
 
 
Figure 4.4. Closed circles (●) represent the propranolol HCl concentrations measured at sampling port D 
and open circles (○) the concentration assessed at A for a 10 mg immediate release tablet (n = 7, all 
values as mean ± stdev). 
 
60 h-1 was found to be sufficiently high, although more measurement point at early time 
points of the experiments might be desirable. Figure 4.4 plots the concentration 
measured at sampling port D and sampling port A against time. Concentration 
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assessed at sampling port D yielded higher concentrations than at sampling port A 
since convectional mixing and dilution throughout the passage of the apparatus 
broadened the peak and decreased peak height. In addition, a time shift between the 
peak maxima at D and at A of approximately 7.5 min was detected. 
 
 
Figure 4.5. Cumulative mass of propranolol HCl calculated according to Eq (26) from the concentration 
obtained at sampling port D is plotted vs. time. After 120 min tablets released 98.7 ± 4.0 % mg of the 
labelled amount (n = 7, all values as mean ± stdev) 
 
Figure 4.5 plots the percentage of released propranolol HCl calculated according to 
Eq (22) against time. An almost complete release of 98.7 ± 4.0 % of the labeled 
amount of propranolol HCl could be detected, thus being a strong indicator for correct 
calibration. Cumulative amount appeared at A yielded a mass of 1.48 mg at 120 min 
(curve not shown). Since the stream splitter is dividing the incoming 6.5 ml min-1 stream 
from the dissolution device into an 1.0 ml min-1 for the apical compartment and a waste 
stream, the mass appeared at A should be 1 / 6.5 = 15.4 % of the amount appeared at 
D. The observed value of 15.5 % matched sufficiently precise the targeted value, 
indicating that flow rates were adjusted correctly and that the stream splitter worked 
properly. Figure 4.6 shows on the primary ordinate the concentration measured at 
sampling port A vs. time, hence the concentration which was led over the Caco-2 
monolayer. The amount of propranolol HCl measured in the basolateral compartment 
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against time is plotted on the secondary axis. It is evident that the greatest increase of 
propranolol HCl in the basolateral compartment is accompanied with the maximum 
peak concentrations at sampling port A.  
 
 
Figure 4.6. Open circles (○) represent the concentration measured at A (primary ordinate), triangles down 
(▼) represent the permeated amount of propranolol HCl derived from concentration measured in the 
basolateral compartment (secondary ordinate). Asterisks indicate the values from the Papp value was 
calculated (n = 7, all values as mean ± stdev). 
 
After 120 min, a total amount of propranolol of 4.07 ± 0.37 µg (n = 7) was detected in 
the basolateral compartment. When forming the ratio between the amount which 
permeated and the cumulative amount appeared at A, a value of 0.275 % is found. This 
value is comparable with values found in literature for high permeability compounds 
[53]. According to Eq (27), apparent permeability (Papp) was calculated from seven time 
points as indicated with asterisks in Figure 4.6. Papp was estimated as      
2.61 ± 0.63 10-5 cm·s-1 (mean of 7 independent calculations). Vogelpoel et al. [59] 
stated that Papp values for propranolol HCl through Caco-2 cell monolayers are reported 
in literature to be in a range of 1.12 ± 0.05·10-5 to 4.30 ± 0.36·10-5 cm·s-1. Therefore, it 
can be pointed out that the value found with the here described apparatus is 
consistent, either with previous experiments of the authors [39] and with literature. 
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Caco-2 monolayers retained their integrity throughout the experiments indicated by a 
TEER before and after each experiment being above 350 Ω·cm2 with blank filter 
subtracted.  
 
4.3.3 Comparison between manual sampling and automated sampling 
 
Synopses of data obtained from manual sampling with quantification by HPLC as 
described in [39] and data obtained from the above described SIA method are 
graphically juxtaposed in Figure 4.7. The same propranolol HCl 10 mg immediate 
release tablets of the same batch were used for both sets of experiments. Before 
interpreting the data, it is worth to mention that aside from automation the apparatus for 
combined measurement of dissolution and permeation underwent some further 
changes compared to the one previously described. The inner diameter of the tubing 
and the length of the tubing were decreased wherever feasible since lag time and time 
shift were found to be improvable. In addition, the volume of the basolateral 
compartment was decreased in order to be able to measure higher concentrations. As 
it can be seen in Figure 4.7, concentration trends at sampling port A and B obtained 
from either manual or automated sample processing appear to be comparable. The 
optimized and automated setup yielded at sampling port D higher peak maximum 
concentrations of approximately 75 µg ml-1 vs. 65 µg ml-1 of the previously described 
apparatus. This may be contributed to the shorter and thinner tubing and to higher 
resolution due to more sampling points. Maximum concentrations derived from 
sampling port A behave similar (57 µg ml-1 vs. 50 µg ml-1). Standard deviation of the 
automated apparatus seemed to increase slightly. This phenomenon might be due to 
the higher sampling volumes of the not automated apparatus where 500 µl of sample 
were withdrawn and analyzed (compared to 25 µl at the SIA). Sampling higher volumes 
will average the concentration variation within this volume and thus apparently decrease 
variation of concentrations. Aside from that, peak shape was not significantly affected. 
By means of the automation, sampling frequency was increased nearly by the factor 
two compared to manual sampling. At the peak concentrations, however, higher 
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sampling frequency for the SIA system would be appreciated. This might be subject for 
 
 
Figure 4.7. Comparison between manual sampling and analysis via HPLC (lower diagram) (n=5) and 
automated sampling and fluorescence detection using SIA (upper diagram) (n=7). Closed circles (●) 
represent the concentrations at D, open circles (○) the concentration measured at A (both primary 
ordinate) and triangles down (▼) represent the permeated amount of propranolol HCl (secondary 
ordinate). 
 
further optimization. The concentration trend measured in the basolateral compartment 
changed only slightly. It appears that for the newer setup a plateau is reached earlier 
(Figure 4.7). The reason for that might be – additionally to shorter tubing – the 
decreased volumes in the basolateral compartment (5.25 ml compared to 10.5 ml). 
However, after 120 min, a comparable amount of propranolol HCl in the basolateral 
compartment was detected (4.07 ± 0.37 µg for SIA vs. 4.23 ± 0.45 µg for manually and 
__________________________________________________________________________________________ 
Automation 
4-73 
HPLC treated samples, respectively). Additionally, decreased standard deviations of the 
concentrations for the automated setup were found for concentrations measured at B; 
however sample number is too small to generalize this finding. Table 4.1 shows in 
summary the mean times at the different sampling ports D, A and B calculated 
according to Eq (3) to Eq (5). Generally speaking, a trend to shorter mean times at the 
different sampling ports can be seen for the automated and optimized apparatus.  
 
 
Table 4.1. Mean times calculated according to Eq (2), Eq (3) and Eq (4) in comparison (n = 5 for manual 
sampling according to data in [39] and n = 7 for SIA analysis) 
 
 Manual sampling followed by  HPLC analysis 
Automated sampling and  
analysis by SIA 
MTD [min] 23.45 ± 0.96 22.32 ± 2.32 
MTA [min] 31.37 ± 1.12 30.35 ± 1.56 
MTB [min] 34.98 ± 2.27 30.02 ± 2.56 
 
Since sampling port D is located very early within the apparatus, only a minor decrease 
of the MTD is be detected. A similar behavior can be observed for sampling port A, 
where the MDA time was slightly decreased in the automated setup. A more 
pronounced effect could be detected for the MTB, which has been calculated from the 
mass increase in the basolateral compartment. Here, the MTB shifted distinctively for 
approximately 5 min. Since the mean times for sampling port D and A did not change 
significantly, the change of the MTB can exclusively be assigned to changed setup. This 
entails that a small change in tubing and dead volumes can greatly effect the 
concentration trends and intends for future studies that comparing results from different 
apparatus for combined measurement of dissolution and permeation is difficult if even 
impossible. 
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4.4 Conclusion 
 
It was possible to automate the apparatus for combined measurement of dissolution 
and permeation of solid dosage forms by means of sequential injection analysis. Two 
limitations of SIA are set concerning sampling frequency and selectivity. Analysis, filling 
and washing requires time and restrict sampling frequency to maximum 60-80 
measurements per hour. In addition, not every API is accessible selectively and 
sensitively via fluorescence, hence forcing the researcher to search for alternative 
solutions for detection. Many aspects of sequential injection analysis supported this 
successful attempt for automation. Flexibility and versatility facilitated rapid sampling 
from different sampling ports with varying washing steps, varying aspiration volumes 
and in case of sampling from sampling port B automated replenishing of the withdrawn 
buffer. Detection with fluorescence permitted sensitive and selective online 
determination and quantification of propranolol HCl in KRB. In addition, online 
measurement could reduce issues when working with unstable compounds. 
Furthermore, automation decreased labor intensive manual sampling and dramatically 
dropped the costs for HPLC accessories.  
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5 Test with a BCS class 4 compound: furosemide 
 
 
Subsequent to the basic testing of the apparatus using a unproblematic compound 
propranolol HCl, the focus of interest was shifted to more sophisticated drug such 
as furosemide, a BCS class 4 compound. Prior to testing permeability of the 
dosage form Lasix®, efforts have been made in order to establish an analytic basis 
for the experiments. Subsequently, experiments with the tablets have been done. 
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5.1 Introduction 
 
In previous chapters, propranolol HCl served as an uncomplicated model drug 
for testing the basic parameters of the apparatus such as cell monolayer integrity, leak 
tightness of the tubing, and the eligibility of automation. However, as discussed in 
section 1.1.2 (pp. 1-4 to 1-7), the here described apparatus is intended to be used - 
among other reasons - for advanced formulation screening for solid oral dosage forms. 
Therefore, the apparatus has to be tested using compounds from more demanding 
BCS classes. As a first step, quantification and automation has to be extended to low 
permeability compounds, especially with a focus on concentration assessment at the 
sampling port B. In order to determine the permeated amount of low permeability 
compounds, HPLC would be the most appropriate since it is a routine method in most 
laboratories and since it exhibits lower LOQ/LOD compared to SIA and allows 
separation prior to quantification. As a model compound for this objective, furosemide 
(frusemide) was chosen showing sufficient UV/VIS absorbance for the assessment of 
concentration at the sampling ports D and A. At sampling port B, however, online 
quantification by means of UV/VIS is not feasible since furosemide does not exhibit 
significant fluorescence in KRB. Prior to testing furosemide by means of combined 
dissolution and permeation assessment, transport experiments in Transwells® were 
performed in order to verify effects of excipients on permeation. 
 
5.1.1 Furosemide as a model substance; biopharmaceutical classification 
 
Furosemid is assigned to BCS class 4 [64], since it shows low permeability in 
Caco-2 permeability assays and low solubility in aqueous buffer systems. Solubility is 
depending strongly on pH as furosemide is a monovalent acid with a pKa of 3.9 [88]. 
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Figure 5.1. Chemical structure of Furosemide. 
 
Therefore, declining pH values decrease solubility of furosemide as it can be seen in 
Figure 5.2. Equilibrium solubility of furosemide in KRB at pH 7.4 was determined as 
approximately 1900 µg/ml, while equilibrium solubility at pH 6.5 is 1500 µg/ml and 
further decreases to 330 µg/ml at pH 5.0 (all values for 24 h stirring at 37 °C of an 
excessive amount of furosemide, values found are correlating well with data reported in 
literature [61]). 
 
Figure 5.2. Solubility of furosemide in KRB is depending in the pH. Note that the experiments have been 
performed with MES for pH values lower than 7 and with HEPES for higher pH values (n = 3 for each 
pH). 
 
In Caco-2 permeability assays, furosemide shows low permeability as well as an 
asymmetric transport [61, 89, 90]. Experiments in our laboratory applying a proton 
gradient between the apical and the basolateral compartment (pH 6.5 apical and pH 
7.4 basolateral) led to the following Papp values: Papp(A-B) 2.12 ± 0.70·10
-7 cm/s and 
Papp(B-A) 1.04 ± 0.068·10
-5 cm/s (Figure 5.3); resulting in a high flux-efflux ratio of 
approximately 50. Values reported in literature are in the same magnitude: Pade et al. 
[61] reported a Papp(A-B) of 1.20 ± 0.10·10
-7 cm/s and a Papp(B-A) of          
2.74 ± 0.02·10-6 cm/s; Rege et al. [89] reported a Papp(A-B) of 4.66 ± 0.29·10
-7 cm/s 
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and a Papp(B-A) of 6.46 ± 0.12·10
-6 cm/s; Hilgendorf at al. [90] reported a Papp(A-B) of 
2.9 ± 0.1·10-7 cm/s. Interestingly, Papp(B-A) was in our lab two to three fold greater 
compared to literature. This might be attributed to the applied proton gradient and to 
different experimental protocols and putatively also to varying Caco-2 clones. 
 
Figure 5.3 Apparent permeability (Papp) of furosemide through Caco-2 monolayer, either in absorptive (A-
B) or in secretory direction (B-A) (n = 12 for each bar). Flux efflux ratio is calculated as approximately 50. 
 
In summary, furosemide can be assigned to BCS class 1 [64], showing low solubility 
especially at low pH values and low permeability in Caco-2 monolayer permeability 
assay. Consequently, furosemide shows poor [88, 91] oral bioavailability of 50% [61] or 
37-51 % [92]. 
 
5.2 Materials and methods 
 
5.2.1 Materials 
 
Transwell® permeable filter inserts (pore size 0.4 µm, 1.13 cm2, Transwell® type 
3460) were purchased from Corning Incorp. Life Sciences (Acton, MA). Dulbecco’s 
modified Eagle’s medium (DMEM), non-essential amino acids (NeAA) and fetal bovine 
serum (FBS) were purchased from GIBCO (Invitrogen Corp. Carlsbad, CA). Furosemide 
(batch 0405A074) was bought from Synopharm GmbH & Co KG (Barsbüttel, Germany). 
Organic solvents were of HPLC grade. Composition of Krebs-Ringer Buffer (KRB) buffer 
was as follows: 1.41 mM CaCl2, 3.00 mM KCl, 2.56 mM MgCl2, 142.03 mM NaCl, 0.44 
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mM K2HPO4, 4.00 mM D- Glucose and 10.0 mM HEPES if pH 7.4 or 10.0 mM MES if 
pH 6.5. KRB was adjusted to pH 7.4 or 6.5 by means of NaOH. All salts for KRB were of 
cell culture tested grade and obtained from Sigma-Aldrich (St. Louis, MO). 
 
5.2.2 Test tablets 
 
Test tablet were: Lasix® 40 mg. According to the package insert, the ingredients 
of a tablet were except furosemide: lactose, corn starch, pre-pasted corn starch, 
talcum, silicon dioxide, and magnesium stearate. Batch number was 40E200. 
 
5.2.3 Cell culture 
 
Caco-2 cultivation has been done as described in section 2.2.2 (p 2-22). 
 
5.2.4 Transport experiments 
 
Transport experiments have been performed using the Transwell® system. Donor 
concentration of furosemide was 20 µg/ml. Transport medium was KRB, whereas the 
apical pH was adjusted to pH 6.5 (MES) and the basolateral pH to 7.5 (HEPES). The 
donor solution was added to the respective compartment (apical 500 µl; basolateral 
1500 µl), and 100 µl samples have been collected hourly for five hours. The withdrawn 
amount was replaced by the respective KRB solution and has been mathematically 
taken in account (Eq (2)). Samples have been analyzed by HPLC and mass increase in 
the acceptor compartment was used to calculate the drug flux across the Caco-2 
monolayer. Then, Papp was calculated by correlation of the flux with the donor 
concentration according to Eq (1). 
 
5.2.5 Apparatus for permeability assessment of complete dosage forms 
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Basically, the apparatus for combined measurement of dissolution and 
permeation of complete solid oral dosage was used as reported in section 2-4 [39, 75]. 
Compared to the setup reported in [39, 75] some changes have been made. Firstly, the 
pump in front of the flow dissolution cell was changed to a pump as claimed by USP 
and Ph. Eur. generating a sinusoidal flow profile (type CE1, Sotax, Lörrach, Germany). 
Secondly, the flow rate in the dissolution module was changed since furosemide shows 
under the more stressing hydrodynamics rather fast and complete dissolution in pH 6.5 
KRB. Therefore, in order to assure correct measurement of the concentrations, the flow 
rate was reduced to 4.5 ml/min. Moreover, the basolateral compartment was changed 
as follows: Since the temporal resolution of the permeated amount was too poor due to 
insufficiently slow mixing in the basolateral compartment. A putative solution might be 
to increase the flow rate in the basolateral compartment to ensure proper mixing; 
however, this might entail problems with the monolayer integrity or evoke other, new 
problems. Therefore, in order to circumvent this issue, the basolateral compartment 
was designed to be open, and drug concentration in the outflow of the basolateral part 
of the FTPC was monitored in the same manner as for sampling port A. All other 
settings have not been changed. 
 
5.2.6 Drug quantification 
5.2.6.1 Quantification of furosemide via HPLC 
Quantification of Propranolol HCl was performed using a Dionex HPLC system, 
implemented with a RP 18 (LiChroSpher® 100, Merck), 5 µm, 12.5 cm column.  
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Figure 5.4. Calibration line for furosemide in HPLC applying the above described HPLC method: peak 
area is plotted against the furosemide standard concentration. The extract shows a magnification for the 
lower standards (5, 10, 20, and 50 ng/ml). 
 
The HPLC system consisted of a Dionex P580 pump, a Dionex ASI 100 auto sampler, a 
UVD 170 S detector and a Dionex STH 585 column oven. Software was Chromeleon® 
6.60, SP 1 build 9.68. Mobile phase was 60% (v/v) water, 20% (v/v) acetonitrile, 10% 
(v/v) methanol, 0.033% (v/v) triethylamine and 0.044% (v/v) phosphoric acid. Flow was 
1.2 ml/min and oven temperature was 40 ± 1 °C. Detection was done with UV at 
235 nm, whereas linearity (R2 > 0.999) was given between 5 ng/ml and 20 µg/ml. 
Retention time was 3.10 ± 0.10 min. It was shown that none of the excipients interfered 
with the analysis. 
5.2.6.2 Automated SIA procedure for furosemide quantification 
 
The SIA system consisted of the FIAlab 3500 (FIAlab instruments, WA, USA) 
implemented with a 2.5 ml piston pump, a peristaltic pump and an eight port 
multiposition valve. Software was FIAlab for Windows® version 5.9.192. Standards were 
aspirated by means of an autosampler (Cetac ASX 260, NE, USA). A rack (material 
polyoxymethylene, POM) for the HPLC vials has been custom made (Figure 8.7, Figure 
8.8). UV light source was purchased from Mikropack (type D-2000, Ostfildern, 
Germany), and was linked with the spectrometer (USB2000, Ocean Optics, Dunedin, 
FL, USA) by means of a fiber optic cable, whereas a FIAlab SMA-Z Flow Cell (Teflon®) 
for absorbance measurements (optical path length 5 mm) was inserted between the 
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light source and spectrometer. Spectrometer setting was as shown in Table 8.3. The 
programs codes for the automated measurement at the respective sampling ports are 
given in sections 8.4.1 (main), 8.4.2 (dissolution), 8.4.3 (apical), 8.4.4 (basolateral) (pp. 
8-115 to 8-118). Port allocation was as given in Table 8.5 (p. 8-121). At D and at A, the 
connecting tubing was washed prior to the analysis by aspiration. Then, for 
quantification, 100 µl at D and at A were aspirated (15 µl/s) and were pushed through 
the detector with a velocity of 30 µl/s, which was found to be the optimal pump rate in 
terms of reproducibility and peak height. For quantification, peak height was correlated 
with furosemide standard concentration.  
For sampling port B, a filling routine was developed since, due to its low 
concentrations, furosemide is not directly quantifiable by means of UV. Consequently, 
the SIA apparatus was used to bottle automatically samples from the basolateral 
sampling port into HPLC (200 µl inserts). The following procedure was shown to be 
superior in terms of recovery and reproducibility among others tested: Prior to 
aspirating the sample, 100 µl of air are aspirated into the coil between the syringe pump 
and the eight port multiposition pump, then 100 µl sample are aspirated and 
subsequently again 100 µl of air are aspirated. In the mean time, the autosampler 
washes its tip and subsequently moves to the waste position. After dispensing 210 µl 
(which is the volume between the multiposition valve and the tip of the autosampler) 
into the waste (50 µl/s), the autosampler tip moves to the respective HPLC vial and 
dispenses 110 µl sample into a vial (25 µl/s). Subsequently, the tip moves again to the 
waste position and discards the remaining volume in the tubing (250 µl/s). In order to 
check recovery and reproducibility, original and "bottled" standards have been 
quantified by HPLC (n = 3). In Figure 5.5, peak area of the original standards is plotted 
against the area of the "bottled" standards. Linear regression leads to the Eq (28). 
 
 y = 0.85579 ± 0.0014 x + 0.00014 ± 0.0008   (value ± std. error) Eq (28) 
 
The slope of 0.85579 can be interpreted as a recovery of 85.58 %, whereas the 
standard error is less than 0.2 %. The tiny offset of 0.00014 suggests low tendency for 
carry over effects or other irregularities.  
 
__________________________________________________________________________________________ 
Test with a BCS class 4 compound: furosemide 
5-83 
 
Figure 5.5. Comparison of the peak area of original standards and standards which have been treated 
according to the procedure given in section 8.4.4 (R2 > 0.9999). The extract shows a magnification for 
the lower standards (0, 5, 10, 20, and 50 ng/ml) 
5.2.6.3 Calibration of furosemide measured by means of SIA 
 
Furosemide exhibits three UV absorbance maxima (235, 275, 344 nm). However, 
due to the measurement in KRB showing significant UV-absorbance up to 250 to 
260 nm, only the area above 270 nm is directly accessible with SIA analysis. Since the 
concentration to be measured throughout the analysis do span over three decades 
(approx. 1 to 1000 µg/ml), three wavelengths have been applied for quantification. 
Absorption at 275 nm was used for the lowest concentrations down to 3.2 µg/ml, 
absorption at 344 nm was applied for concentrations in a range of 30 to 150 µg/ml, and 
absorption at 360 nm was used for the highest concentration up to 800 µg/ml 
furosemide in KRB.  
 
Table 5.1. Calibration parameters for various wavelength of furosemide in KRB. The calibration follows a 
linear equation y = ax+b [µg/ml]. 
 
wavelength a b R2 range [µg/ml] 
275 nm 0.0344 -0.0329 > 0.9999 3.2 - 32 
344 nm 0.00619 -0.0197 > 0.9999 32 - 160 
360 nm 0.00149 -0.00024 0.99976 160 - 800 
 
Standards have been prepared at the following concentrations: 0, 3.2, 8, 16, 32, 80, 
160, 320, and 800 µg/ml; each standard has been measured ten times. A typical 
calibration for these three wavelengths is shown in Figure 5.6, Figure 5.7, Figure 5.8. 
__________________________________________________________________________________________ 
Test with a BCS class 4 compound: furosemide 
5-84 
Calibration factors are summarized in Table 5.1. Limit of quantification for the calibration 
at 275 nm was calculated as 1 µg/ml (10σ)  
 
Figure 5.6. Calibration for 275 nm for furosemide in KRB (R2 > 0.9999). 
 
 
Figure 5.7. Calibration for 344 nm for furosemide in KRB (R2 > 0.9999). 
 
 
Figure 5.8. Calibration for 360 nm for furosemide in KRB (R2 = 0.9976) 
 
Relative standard deviation (srel) for the lowest standard (3.2 µg/ml) was 2.31 % and for 
the highest standard 0.82 % (n = 10). For all other standards in between srel never 
exceeded 2.4 % (n = 10). 
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5.2.7 Data treatment 
 
Concentration time trends at the sampling ports have been fitted to Eq (29) 
 
 c = kΩ ab-aΩ(e
-aΩx-e-bΩx)      Eq (29) 
 
using SigmaPlot 2004 for windows version 9.0 (bateman equation). For the fitting a 
kinetic model for a exponential invasion of furosemide into a assumed compartment 
and an exponential elimination out of the compartment. For sampling ports A and B, a 
time shift was taken into consideration. The cumulative amount at sampling port D has 
been calculated according to Eq (26). Mean times for the various sampling ports have 
been calculated according to Eq (3) to Eq. (5). 
All values are denoted as mean ± standard deviation if not denoted different. 
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5.3 Results and Discussion 
 
5.3.1 Furosemide in Caco-2 transport experiments – impact of excipients 
 
It has been reported that apparent permeability of furosemide can be affected by the 
presence TWEEN 80 (Figure 5.10). Rege et al. [89] reported to increase the absorptive 
Papp(A-B) from 4.66 ± 0.29·10
-7 cm/s to 3.49 ± 0.35·10-6 in presence of 1.8 mg/ml 
TWEEN 80 and hence to neutralize the asymmetry in transport without toxic effects on 
Caco-2 cell monolayers. Preliminary studies in order to confirm these results have been 
done using vitamin E TPGS (Figure 5.9) and TWEEN 80 (Figure 5.10) at various 
concentrations.  
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Figure 5.9. Chemical structure of vitamin E TPGS (d-alpha-tocopheryl poly(ethylene glycol) 1000 
succinate), a polyethoxylated (n = 23) vitamin E derivative with a succinic acid linker. 
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Figure 5.10. Chemical structure of TWEEN 80, a polyethoxylated fatty sorbitan acid ester, R = oleic acid. 
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5.3.1.1 Impact of vitamin E TPGS 
Vitamin TPGS was tested at two concentrations: 33 µM and 100 µM. (CMC of vitamin E 
TPGS approx. 100 µM). A 33 µM vitamin E TPGS solution exhibited maximum inhibitory 
effects on P-gp as stated by Collnot et al. [17] and equalized apical to basolateral and 
basolateral to apical transport of rhodamine 123. For furosemide, however, a complete 
depletion of polarity in transport could not be achieved by means of vitamin E TPGS. 
Results are visualized in Figure 5.11. Papp(A-B) was increased from           
2.12 ± 0.70·10-7 cm/s to 3.59 ± 0.33·10-7 cm/s in presence of 33 µm vitamin E TPGS 
and to 3.46 ± 0.35·10-7 cm/s in presence of 100 µM vitamin E TPGS. Differences in A to 
B transport were statistically different. (t-test, p < 0.001). Papp(B-A) was reduced by 
33 µM vitamin E TPGS from 10.4 ± 0.68·10-6 cm/s to 8.78 ± 0.31·10-6 cm/s and for the 
100 µM solution to 6.68 ± 0.16·10-6 cm/s. Again, a statistical difference could be found 
(t-test, p < 0.001).  
 
Figure 5.11. Impact of Vitamin E TPGS on furosemide transport in secretory (BA) and absorptive (AB) 
direction (n = 5-6 for each column). 
 
5.3.1.2 Impact of TWEEN 80 
TWEEN 80 was added in three concentrations: 1.0 mM, 1.5 mM, and 2.0 mM 
which correspond to 1.31 g/l, 1.965 g/l, and 2.620 g/l. Rege et al. [89] proposed to 
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apply a 1,8 g/l TWEEN 80 solution for Caco-2 experiments in order to simulate 
physiologic conditions and relevant concentrations. Application of TWEEN 80 increased 
apical to basolateral and decreased basolateral to apical permeability suggesting that 
TWEEN 80 interferes with cellular efflux systems (results are summarized in Figure 5.12. 
Papp(A-B) was statistically significantly (p <0.001, Holm Sidak, one way ANOVA) 
increased to 6.18 ± 0.30·10-7 cm/s (1.0 mM), to 6.57 ± 0.16·10-7 cm/s (1.5 mM), and to 
9.32 ± 0.45·10-7 cm/s (2.0 mM). Papp(B-A) was statistically significantly decreased from 
10.4 ± 0.68·10-6 cm/s to 5.76 ± 0.17·10-6 cm/s (1.0 mM), 5.47 ± 0.20·10-6 cm/s 
(1.5 mM), 5.38 ± 0.43·10-6 cm/s (2.0 mM). Accordingly, the flux efflux ratio was 
decreased from 50 to 9.3, 8.33, and 5.8, respectively. In contrast to the findings of Rege 
et al [89], no complete neutralization of the flux efflux ratio was found. Nevertheless, a 
similar trend has been observed. Putatively, varying batch to batch quality of TWEEN 80 
might lead to scattering results. Also, Caoc-2 cells used by Rege et al. [89] might have 
had different expression pattern of the efflux protein. 
 
Figure 5.12. Impact of TWEEN 80 at various concentrations on furosemide transport in secretory (BA) 
and absorptive (AB) direction (n = 5-6 for each bar). 
 
 
 
__________________________________________________________________________________________ 
Test with a BCS class 4 compound: furosemide 
5-89 
5.3.2 Combined measurement of dissolution and permeation of Lasix® tablets 
5.3.2.1 Concentration time trend at sampling port D 
Sampling port D is located directly after the flow through dissolution cell and is 
delivering dissolution signals which are almost not affected by mixing and convectional 
processes. The right plot in Figure 5.13 plots the concentrations assessed at sampling 
port D against time. 
 
Figure 5.13. Left plot: concentration time trend at sampling port D for Lasix® tablet containing 40 mg 
furosemide. Right plot: cumulative amount of furosemide assessed at sampling port D (n = 6) 
 
 
Maximum concentrations were reached at approximately 3.5 min. The cumulative 
amount has been calculated according to Eq (26), and percentage dissolved and 
detected is plotted against time in Figure 5.13. After 60 min, a cumulative amount of 
99.03 ± 1.95 %, i.e. 39.61 ± 0.78 mg, of the declared amount (40 mg) were detected. 
When applying Eq (28) to the data shown above, a nice correlation of the fitting is 
observed as illustrated in Figure 5.14 (R2 = 0.9986). The variables obtained from linear 
regression are summarized in Table 5.2. Mean time assessed with Eq (3) is given in 
Table 5.3.  
__________________________________________________________________________________________ 
Test with a BCS class 4 compound: furosemide 
5-90 
 
Figure 5.14. Concentrations of furosemide at sampling port D fitted to a bateman equation according to 
Eq (12); R2 = 0.9986. 
 
5.3.2.2 Concentration time trend at sampling port A 
Concentration assessed at sampling port A are plotted against time in Figure 
5.15. A time shift of approximately 9 min is observed (peak to peak difference).  
 
 
Figure 5.15. Left plot: concentration time trend at sampling port D for Lasix® tablet containing 40 mg 
furosemide. Right plot: cumulative amount of furosemide assessed at sampling port D (n = 6) 
 
Furthermore, the peak appears to be flattened and stretched. Maximum concentrations 
were reached at 12.5 min post experiment beginning. In order to fit the curve at A to 
Eq (25), the peak was shifted for 12.5-3.5 min = 9 min to the left in order to assure that 
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the peak is going through the origin (Figure 5.16). Fit parameters are summarized in 
Table 5.2.  
 
Figure 5.16. Concentrations of furosemide at sampling port A fitted to a bateman equation according to 
to Eq (12); R2 = 0.9899. 
 
5.3.2.3 Concentration time trend at sampling port B 
The concentrations at sampling port B are assessed according to the previously 
described filling procedure and HPLC method. The concentrations are corrected for the 
 
Figure 5.17. Concentration of furosemide in the outflow of the FTPC is plotted against time (n = 6). 
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loss of substance during the filling procedure and are plotted against time in Figure 
5.17. Evidently, highest concentrations in the outflow are accompanied with the peak 
concentrations at sampling port A. TEER remained above 500 Ω·cm2 during all 
experiments. For fitting, the curve was also shifted to the left by 9 min as described 
above. (Figure 5.18). Mean times for sampling port B are given in Table 5.3.  
 
Figure 5.18. Concentrations of furosemide at sampling port B fitted to a bateman equation according to 
Eq (12); R2 = 0.9970. 
 
The cumulatively permeated amount was calculated as 38.06 ± 5.89 µg according to 
Eq (23). In comparison to the amount cumulatively appeared at sampling port A 
(6,591.36 ± 132.46 µg), a ratio of 0.577 % was able to permeate. 
 
Table 5.2. Parameter obtained from linear regression according to Eq. (25) 
sampling 
port 
time shift 
[min] k a b R
2 
D 0 3681.59 0.1677 0.4082 0.9986 
A 9 5312.66 0.1247 0.9189 0.9899 
B 9 38686.0 0.1359 1.2168 0.9970 
 
Table 5.3. Mean times for sampling ports D, A, and B. 
 at D: MTD at A: MTA at MTB 
mean time 10.15 ± 1.00 24.74 ± 0.39 21.97 ±1.75 
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5.3.2.4 Discussion of the furosemide/Lasix® results 
 
Preliminary tests using membrane dosage pumps in the dissolution module as done in 
previous sections yielded unsatisfactory results concerning the dissolution process. It 
appeared as if low hydrodynamic stress in the flow through dissolution cell led to 
irreproducible, incomplete, and delayed dissolution behavior of the tablets. By contrast, 
the application of a compendial dissolution pump generating a sinusoidal flow profile 
and resulting in higher hydrodynamic stress on the dosage form led to rather fast 
dissolution. Release of 40 mg furosemide was completed within 30 min resulting a MDD 
of ~10 min, which is much lower than the MDD for propranolol HCl with ~22 min 
(compare Table 4.1, p 4-73). Maximum concentrations assessed at sampling port D 
were in mean 800 µg/ml and were close to maximum solubility of furosemide in pH 6.5 
KRB. Although furosemide powder shows severe wetting problems in KRB pH 6.5, the 
tablet showed no wetting issues and behaved concerning its dissolution properties 
more or less as an immediate release dosage form. This might be attributed to 
furosemide highly dispersed within the insoluble corn starch. The cumulative amount at 
sampling D of 99.03 ± 1.95 % indicates proper calibration and correct adjustment of 
the flow rate.  
 
Figure 5.19. Graphical summary of Lasix® 40 mg furosemide tablets. Closed circles (●) represent the 
concentration time trend at sampling port D, open circles (○) at sampling port A, and triangles down (▼) 
at sampling port B. 
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Number of data points of this sampling port can be considered as sufficiently high. At 
sampling port A, a similar peak shaped concentration time profile can be observed. 
Maximum peak time shifted from 3.5 min to 12.5 min and the peak height was declined 
from ~800 µg/ml at D to ~500 µg/ml at A. Accordingly, mean time at A was greater 
than mean time at D. Though the peak to peak time difference was 9 min, the mean 
time are differing by ~15 min. This might be explained by the stronger 'tailing' of the 
peak at sampling port A apparently increasing the mean time at sampling port A.  
Concentrations at sampling port B resulted also in a peak shaped curve (Figure 5.17). 
The setup has been altered to an open compartment since mixing in the basolateral 
compartment was insufficient. The cumulative amount of permeated furosemide was 
rather high (0.577%) and exceeded the permeated amount of propranolol HCl 
(~0.35%, compare Table 2.4). Several reasons may be accounted for that: First, a 
leakage in the FTPC may lead to high permeated amounts. Second, the cell monolayer 
is disrupted by the analysis, or third, high concentrations saturate efflux transporters. 
The first possibility can clearly be excluded since in not even one past experiment, a 
leakage in the FTPC has been detected. The second possibility may be rebutted since 
the cell monolayer showed high TEER values after the experiments and were 
microscopically intact. Potentially, high concentrations of furosemide and lactose might 
affect with their osmolarity cell monolayer integrity. At the peak concentrations, for 
example, 500 µg/ml furosemide are adding another 15.2 mOsmol/kg to the osmolarity 
of KRB of approximately 300 mOsmol/kg; for lactose no numbers can be given, since 
the amount of lactose per tablet is unknown. However, the osmotic effects remains 
unclear since Caco-2 cells are generally not that sensitive, if the osmotic stress persists 
only for a short time. The third possibility is still to be clarified with static transport 
experiments at higher concentrations.  
In summary, a method for assessing reproducibly dissolution process with the 
apparatus for permeability assessment of drug formulated in solid dosage forms has 
successfully described. For the permeation process, however, a deeper study to reveal 
the processes happening on the permeation stage has to be done in the future. 
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5.4 Conclusion 
 
Transport experiments revealed the impact of TWEEN 80 and vitamin E TPGS on 
the barrier properties of Caco-2 cell monolayers. Both surfactant were shown to 
increase Papp(A-B) and to decrease Papp(B-A). Hence, a suitable candidate was found 
for elucidation dissolution and permeation processes with the newly setup apparatus. 
The automated analytic has been expanded to UV VIS measurement, and a 
filling routine for offline HPLC analysis has been successfully implemented; thus, 
allowing to measure compounds with the apparatus lacking significant fluorescence in 
KRB.  
Furthermore, the apparatus for permeability assessment of solid oral dosage 
formulations was successfully used for measuring a marketed product containing 
40 mg furosemide. Concentrations assessed at sampling port D and A were 
reproducible, plausible and recovery was satisfactory. Fitting the concentration time 
profiles at all sampling ports to a bateman equation led to high coefficients of 
determination in comparison to previous experiments with propranolol HCl. This might 
be attributed to improved hydrodynamics within the apparatus. Concentrations 
assessed at sampling port B were indeed reproducible but the permeated amount was 
too high for a BCS class 4 compound, although the monolayer retained its integrity. A 
putative reason for that might be the tremendously high donor concentrations 
(500 µg/ml) affecting reversibly Caco-2 monolayer integrity and allowing high amounts 
of furosemide to permeate. This phenomenon poses an urgent field of research for 
future studies. 
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6 Summary 
 
Determination of in vivo performance of solid oral dosage forms is mainly based 
on two in vitro assays: in vitro dissolution testing applying in vivo relevant dissolution 
parameters, and cell culture based in vitro permeability assays employing monolayers 
of the small intestinal cell line Caco-2. Both assays have been evolved since decades; 
nevertheless, they exhibit some major drawbacks. Permeability testing in Transwell® 
systems determines intrinsic permeability of pure compounds and thus questions 
discriminatory power: first, the presence of endogenous (e.g. bile salts) or exogenous 
(e.g. dosage form excipients, food) substances affecting permeation processes is often 
neglected. Second, donor concentrations tend to be arbitrarily chosen and are 
assumed to be constant over time in contrast to in vivo. Therefore, it appears 
cumbersome to determine two processes happening in vivo concomitantly in an in vitro 
assay separately. Hence, the aim of this work was to connect both assays in one 
apparatus and to develop an assay eligible to determine in vitro permeability of solid 
dosage forms.  
The recently setup prototype consists of two modules: a dissolution and a 
permeation module (Figure 6.1). In order to connect both, a stream splitter providing 
appropriate low flow rates for the sheer stress sensitive Caco-2 monolayer was 
installed.  
 
Figure 6.1. Schematical depiction of the apparatus for permeability assessment of solid dosage forms. 
Sampling ports are indicated with capital letter: D (dissolution), A (apical), B (basolateral). 
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The dissolution module was open, whereas the transmucosal receptor 
compartment was closed. Several sampling ports were implemented to monitor 
thoroughly dissolution and permeation: sampling port D (dissolution), shortly after the 
USP apparatus 4, sampling port A (apical), after the stream splitter and after passage 
through the flow through permeation cell (FTPC) and finally sampling port B 
(basolateral), in the acceptor compartment. For test purposes, several propranolol HCl 
immediate release tablets with increasing dosage strength and two different propranolol 
HCl extended release tablets were manufactured. For those tablets, experiments 
showed that the permeated amount is linear dependent on the dosage strength as for 
the passively permeating compound expected. For the extended release tablets, a 
delay in release of propranolol HCl from the solid dosage form was visible in the 
permeation profile; nevertheless, the cumulatively permeated amount was not 
statistically different among the differently releasing tablets. Mean time approach for the 
different sampling ports D, A, and B yielded plausible and conclusive results for this 
setup. Also, the stream splitter was found to work reliable. Advantage of such setup can 
be seen in the hydrodynamically separated modular setup providing the possibility to 
employ the dissolution module with compendial, sinusoidal flow profile generating 
pumps. A major improvement may be seen in the possibility to use complete solid 
dosage forms together with physiological flow rates/volumes in the dissolution module; 
and thus, facilitating the application of relevant concentrations. In addition, three 
sampling ports are allowing thorough monitoring of both dissolution and permeation.  
In order to improve the understanding of the processes occurring in the 
apparatus, it was attempted to describe concentration time trends at the three sampling 
ports by computational simulation. The in silico model based on several hypotheses. 
The apparatus was separated into several compartments such as the flow through 
dissolution cell, the stream splitter, and the apical compartment in the flow through 
permeation cell. Consequently, the tubing in between and connecting those 
compartments were modeled according their actual inner diameter and length. In order 
to model the peak broadening, the stream in the tubing was described by the law of 
Hagen Poisseuille, which characterizes a parabolic flow profile in the tubing. The 
release of drug from the dosage form was described by means of a Weibull distribution. 
In order to calibrate the in silico model, the concentration time trend of a propranolol 
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HCl solution applied into the flow through dissolution cell was modeled and parameters 
such as flow rate, compartment size, and other variable have been optimized. 
Subsequent to calibration, the concentration time trends for the various propranolol HCl 
tablets with varying content and release kinetics were successfully simulated. (...) 
Subsequent to the early testing of the prototype, work time for sampling and 
drug quantification was found to be suboptimal. Therefore, the system was automated 
by means of sequential injection technique (SIA). Quantification at the three sampling 
ports was done in this first study via fluorescence measurement. An appropriate volume 
of sample was aspirated from the respective sampling port, and subsequently, the 
sample volume was processed and finally pushed through the flow through 
fluorescence detector. Signal height was then correlated with standards concentrations, 
and a good correlation was found for the sample analyzed at sampling port B showing 
the lowest concentration to be assessed. In order the quantify propranolol HCl at 
sampling ports D and A, where comparatively high concentration appear, the injection 
volume was decreased to extend linearity of the calibration function. Nevertheless, it 
was not possible for sampling D and A to fit the calibration function to a straight line, 
and an appropriate calibration was done by means of a first order polynomial equation. 
Automation almost doubled sampling frequency and decreased error probability 
possibly caused by manual sampling. A comparison of the results obtained with the 
automated setup revealed similar results to those from the manual. The automated 
apparatus allows online measurement at the three different sampling ports D, A, and B 
or partially online analysis in combination with HPLC. For the future, the automation 
facilitates more and faster experiments as well as higher reproducibility of the 
measurement due to less error sources. 
After this extensive testing and development of the apparatus, the next target 
was to be able to measure more sophisticated compounds, and a suitable candidate 
for further studies was chosen as furosemide. Furosemide shows low intrinsic 
permeability through Caco-2 monolayers and is apparently subjected to a cellular efflux 
pump. Apical to basolateral and basolateral to apical permeability can be influenced in 
presence of surface active excipients such as TWEEN 80 and vitamin E TPGS. 
For the assessment of permeability from solid dosage forms, a marketed tablet 
(Lasix®) was used. Prior to this analysis, a quantification method for the SIA analysis 
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had to be developed. Since furosemide shows almost no fluorescence signal in 
aqueous media, quantification has been done via UV/VIS at sampling ports D and A 
and at sampling port B via HPLC. For sampling port B, an automated bottling 
procedure was successfully developed. Dissolution of 40 mg furosemide in pH 6.5 KRB 
was rather fast; however, the concentration time trends at sampling ports D and A were 
measured correctly. Nevertheless, at sampling port B, more data points would be 
desired. Recovery of furosemide at sampling port D was sufficiently high (~98 %), the 
permeated mass, however, was estimated as too high for a low permeability 
compound. Still, it remains unclear whether those high permeated amount is a 
consequence from efflux saturation or from osmotic cytotoxicity. 
In the future, the system may be enhanced in order to simulate the pH gradient a 
drug undergoes after oral administration. Furthermore, the media for 
permeation/dissolution testing has to be refined so that results with higher in vivo 
relevance may be obtained. However, it has to be kept in mind that improving the 
apparatus in such way, entails that also the complicity of the system and efforts for the 
experiments are increasing. 
In summary, a versatile tool for assessing drug permeability of solid dosage 
forms has been developed. Flow rates in the dissolution module are easily and freely 
adjustable, and also the type of dissolution pump is interchangeable. Depending on the 
desired temporal resolution of the permeation process, the basolateral compartment 
can be open or closed. Consequently, the automation was attempted to be versatile 
and flexible, too. Drug quantification at the respective sampling ports can be performed 
with either fluorescence, UV/VIS - both as online analysis -, or with an offline HPLC 
analysis. Combining all these properties, a rather unique tool to estimate dosage form 
interference with biological systems has been developed. 
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7 Zusammenfassung 
 
Prädiktive Urteile zum in vivo- Verhalten fester oraler Arzneiformen nach ihrer 
Applikation basieren hauptsächlich auf Ergebnissen zweier Methoden: Zum einen auf 
in vitro Dissolutionversuchen und zum anderen auf in vitro Permeationsversuchen, 
welche meist eine zellkulturbasierte Permeabilitätsanalyse zu Hilfe ziehen. Beide 
Methoden werden seit Jahrzehnten weiterentwickelt und eingesetzt. Nichtsdestotrotz 
beinhalten diese entscheidende Nachteile: Mit Hilfe von Permeabilitätsanalysen in 
sogenannten Transwell® Systemen wird die intrinsische Permeabilität reiner 
Substanzenlösungen bestimmt, was die prädiktive Aussagekraft solcher Versuche in 
Frage stellt: Zum einen werden die gleichzeitige Anwesenheit und somit die möglichen 
positiven oder negativen Einflüsse von endogenen (z.B. Gallensalze) oder exogenen 
(z.B. Hilfsstoffe) Substanzen auf die Permeabilität vernachlässigt. Zum anderen scheint 
die Donorkonzentration beliebig und eher nach analytischen Aspekten gewählt als nach 
in vivo Relevanz. Aus diesem Grund erscheint es dingend angebracht, beide Prozesse - 
Permeation und Dissolution - gemeinsam in einer Prüfungsanrodnung zu bestimmen. 
Ziel dieser Arbeit war es, beide Methoden in einer Apparatur für feste orale 
Arzneiformen zu kombinieren.  
 
Figure 7.1. Schematischer Aufbau der Apparatur zur Permeabilitätsbestimmung von Arzneistoffen aus 
festen oralen Arzneiformen. Die Probennahmepunkte sind mit den Großbuchstaben D (dissolution), A 
(apikal) und B (basolateral) gekennzeichnet. 
 
Die hierbei entwickelte Apparatur besteht sinngemäß aus zwei Modulen (Figure 7.1): 
einem Dissolution und einem Permeationsmodul, wobei ein Stromteiler die beiden 
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Module miteinander verbindet. Ein Stromteiler ist notwendig, da das Permeationsmodul 
auf Grund der dort vorhandenen Zellschichten im Vergleich zum Dissolutionsmodul 
einen geringeren Flüssigkeitsbedarf benötigt. Die Testapparatur wurde offen geplant, 
sodass ein An- und Abfluten des Arzneistoffes beobachtet werden kann; das 
basolaterale Kompartment im Permeationsmodul wurde jedoch geschlossen geplant. 
Verschiedene Probennahmepunkte wurden installiert um die Konzentrations-
Zeitverläufe gründlich zu überwachen. Probennahmepunkt D (Dissolution) wurde kurz 
nach der Durchflussdissolutionszelle installiert, Probennahmepunkt A (apikal) wurde am 
Ausfluß der Durchflusspermeationszelle eingefügt. Letztendlich wurde der Proben-
nahmepunkt B (basolateral) eingerichtet, welcher die Menge an permeierter Substanz 
im basolateral Kompartment zu bestimmen erlaubt.  
Um die Testapparatur zu testen, wurden verschieden schnellfreisetzende 
Propranolol HCl Tabletten mit ansteigendem Gehalt sowie zwei modifiziert freisetzende 
Propranolol HCl Tabletten produziert und vermessen. Es zeigte sich, daß mit 
ansteigendem Gehalt an Propranolol HCl pro Tablette die permeierte Menge 
proportional ansteigt, was mit den Erwartungen für eine passiv permeierende Substanz 
übereinstimmt. Für die verschieden schnellfreisetzenden Tabletten ergab sich, daß das 
Ausmaß der Verzögerung der Freisetzung in gleichem Verhältnis im Permeations-
prozess wieder sichtbar ist, wobei sich die kumulativ permeierte Menge zwischen den 
verschieden freisetzenden Tabletten nicht statistisch signifikant unterscheidet. Weiterhin 
ergab die Zuhilfenahme des so genannten Ansatzes der "mittleren Dissolution- und 
Permeationszeit" für die Testapparatur plausible und schlüssige Ergebnisse. Ebenso 
konnte die exakte Arbeitsweise des drucklosen Stromteilers bewiesen werden. 
Abgesehen von der Verwendung kompletter Arzneiformen zur 
Permeabiltätsbestimmung durch Caco-2 Zellen ist der Vorteil der hier aufgestellten 
Apparatur insbesondere in ihrem modularen Aufbau sowie in ihrer daraus 
resultierenden Vielseitigkeit und Flexibilität zu sehen. Durch die hydrodynamische 
Trennung von Dissolutions- und Permeationsmodul können vom Arzneibuch geforderte 
Dissolutionspumpen verwendet werden, welche ein sinusoidales Flußprofil erzeugen 
und somit prinzipiell inkompatibel mit druckschwankungssensitiven Caco-2 
Zellmonolayer sind. Des weiteren können die Flußraten in beiden Modulen in gewissen 
Grenzen unabhängig voneinander verändert werden, was die Methodenentwicklung für 
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die Dissolutionsmessung erheblich erleichtert und es somit ermöglicht, Konzentrationen 
im Permeationsmodul mit in vivo Relevanz zu erzeugen.  
In einem weiteren Teilprojekt wurde anschließend versucht, ausgehend von den 
erzeugten Daten die Konzentrations-Zeit Verläufe an den verschiedene 
Probennahmepunkte D, A und B zu modellieren. Motivation hierfür war, das Verständnis 
für die Apparatur zu verbessern und künftig Experimente auf ihre Schlüssigkeit mit 
einem Computermodell überprüfen zu können. Das der Modellierung zu Grunde 
liegende Modell läßt sich folgendermaßen beschreiben: Die Apparatur wurde in 
verschiedene Kompartimente geteilt, so die Durchflussdissolutionszelle, der 
Probenteiler und die apikale Seite der Durchflusspermeationszelle. Die so erzeugten 
Kompartimente wurden mit den tatsächlichen Ausmaßen entsprechenden Leitungen 
verbunden. In diesen Leitungen wurde die Fortbewegung von Substanzteilchen mit 
Hilfe eines parabolischen Flussprofiles nach den Vorgaben des Gesetzes nach Hagen-
Poiseuille beschrieben. Die Freisetzung aus der Arzneiform wurde mit Hilfe einer 
Weibull-Verteilung dargestellt. Um das so aufgestellte Model und seine Parameter, wie  
- beispielsweise Flußverhältnis - zu kalibrieren und zu validieren, wurden die 
Konzentrations-Zeit Verläufe einer in die Durchflussdissolutionszelle eingebrachten 
Propranolol HCl Lösung modelliert. Nach der Kalibrierung wurden die Konzentrations-
Zeit Verläufe für die verschiedenen Propranolol HCl Tabletten berechnet und mit den 
experimentellen Daten verglichen. 
Nach ersten erfolgreichen Tests der Apparatur stellte sich die Frage nach einer 
Automatisierung. Manuelle Probennahme und -analytik schienen zu zeitaufwendig und 
behinderten ein weiteres schnelles Vorankommen. Von den verschiedenen möglichen 
Automatisierungsstrategien erschien die sequentielle Injektionsanalyse (SIA) am 
erfolgversprechendsten. Für die Quantifizierung in den ersten Studien wurde die 
Fluoreszenz von Propranolol HCl in KRB verwendet. Hierfür wurde an den 
verschiedenen Probennahmepunkten ein geeignetes Probenvolumen automatisiert in 
die Halteschleife aspiriert, um anschließend diese Probe durch den 
Fluoreszenzdetektor zu schieben. Die hierbei erhaltene Peakhöhe würde mit 
Propranolol HCl Standardkonzentrationen korreliert.  
Im Rahmen der Automatisierung erwies vor allem die große Bandbreite an zu 
messenden Konzentrationen als Herausforderung. Aus diesem Grund wurden für die 
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Probennahmepunkte D und A geringere Probenvolumen in den Detektor injiziert, um 
den linearen Bereich zu erweitern. Gleichzeitig wurde für den Probennahmepunkt B ein 
größeres Volumen verwendet. Nach erfolgter Kalibration wurden 10 mg Propranolol HCl 
Tabletten mit der automatisierten Testapparatur erfolgreich vermessen. Mit Hilfe der 
Automatisierung konnte die Probennahme- und Analysenfrequenz im Vergleich zum 
manuellen Ansatz nahezu verdoppelt werden. Gleichzeitig wurde es ermöglicht, die 
Apparatur ohne Aufsicht zu betreiben, was den Durchsatz erheblich erhöhte.  
Nach diesem ausführlichen Testen und Entwickeln der Apparatur gerieten 
Arzneistoffe aus problematischeren BCS Klassen in den Fokus des Interesses. hierbei 
wurde insbesondere Furosemid (Lasix®) wurde hierbei als möglicher Kandidat in 
Erwägung gezogen. Der Arzneistoff weist eine niedrige intrinsische Permeabilität durch 
Caco-2 Zellmonolayer auf, und sein Transport unterliegt einer ausgeprägten Polarität. 
Weiter läßt sich die Polarität des Transportes durch Zugabe geeigneter Hilfsstoffe wie 
TWEEN 80 oder Vitamin E TPGS beeinflussen. Vor der eigentlichen Messung der Lasix® 
Tabletten mußte jedoch die Analytik auf die neuen Bedürfnisse angepaßt werden. 
Furosemid zeigt keine Fluoreszenz in salzhaltigen, wäßrigen Medien und ist deshalb an 
den Probennahmepunkten D und A nur per UV-Messung zugänglich. Auf Grund der 
niedrigen Konzentration im basolateralen Probennahmepunkt wurde weiterhin eine 
Methode entwickelt, um Proben automatisch in HPLC Probenbehälter abzufüllen und 
anschließend offline per HPLC zu analysieren. 
Die Freisetzung von Furosemid aus Lasix® in KRB pH 6.5 ging vergleichsweise 
schnell vonstatten, und die Wiederfindungsrate am Probennahmepunkt D war mit etwa 
98 % ausreichend hoch. Am Probennahmepunkt B wurde jedoch eine zu hohe und 
bislang noch nicht zu erklärende Konzentration festgestellt. Mögliche Ursachen für 
dieses Verhalten könnten eine Sättigung des Effluxtransporters durch hohe 
Donorkonzentrationen oder reversible, durch osmotischen Druck vermittelte Effekte auf 
den Caco-2 Monolayer und seine Zell-Zell-Verbindungen sein. Dies wird in 
anschließenden Studien zu klären sein. 
In Zukunft könnte die hier entwickelte Testapparatur wie folgt weiterentwickelt 
werden. Zum eine fehlt der Testapparatur noch die Möglichkeit den pH Wertverlauf, den 
eine Substanz nach oraler Applikation erfährt, zu simulieren. Zum anderen sollte das 
Dissolutionsmedium derart modifiziert werden, daß seine Eigenschaften näher an der 
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tatsächlichen in vivo Situation liegen und die Ergebnisse somit mehr in vivo Relevanz 
erlangen. 
Zusammenfassend läßt sich sagen, daß erfolgreich ein vielseitiges und äußerst 
flexibles Werkzeug zur Bestimmung der Permeabilität fester, oraler Arzneiformen 
entwickelt wurde. Flußraten in den Modulen lassen sich weitestgehend frei einstellen; 
auch die Art der Pumpe im Dissolutionsmodul läßt sich frei wählen. Des weiteren weist 
die Apparatur einen hohen Grad an Automatisierung auf, was den Durchsatz erheblich 
steigert und mögliche Fehlerquellen minimiert. Hierbei stehen verschiedene 
Quantifizierungsmethoden zur Auswahl - so UV/VIS, Fluoreszenz oder HPLC- Messung 
- zur Wahl. 
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8.1 List of abbreviations 
 
BCS biopharmaceutical classification system 
CMC critical micelle concentration  
FIA flow injection analysis 
FTPC flow through permeation cell 
HEPES N-2-hydroxyethylpiperazine- N'-2-ethane sulfonic acid 
HPLC high performance liquid chromatography 
KRB Krebs Ringer buffer 
LOD limit if detection 
LOQ limit of quantification 
MES morpholino ethane sulfonic acid 
Papp apparent permeability 
Papp(A-B) apparent permeability in absorptive direction (apical - basolateral) 
Papp(B-A) apparent permeability in secretory direction (basolateral - apical) 
POM polyoxythylene 
RMSD route mean square deviation 
SIA sequential injection analysis 
srel relative standard deviation 
UV ultra violet light 
VIS visible light 
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8.2 Standard operating procedure for the automated setup 
8.2.1 Preparation:  
 
8.2.1.1 Preparing the devices 
 Turn on the UV lamp (burn in time: 45 min) and all other SIA devices. Manually 
log on all devices to the controlling computer. 
 Heat the water bath to 37.0 ± 0.1 °C. 
 Preheat all buffers prior to degassing to approximately 30 °C. 
 Degas the carrier solvent for SIA (Millipore® water) by means of magnetically 
stirring for ten minutes in a 2 l feeding bottle (VWR 519-4125) under reduced 
pressure generated by a vacuum pump. Change the carrier water and its bottle 
at least once a weak. 
 Degas all buffers by magnetically stirring for ten minutes in a 2 l feeding bottle 
(VWR 519-4125) under reduced pressure generated by a vacuum pump. 
 Purge all tubing with the respective degassed buffers. Therefore, open the 
basolateral compartment and adjust flow rate of the SIA peristaltic pump to 40 
arbitrary units (approx. 1.9 ml/min). Purge the dissolution module (> 6 ml·min-1) 
as well as the apical compartment (1 ml·min-1) for at least 30 min. Purge the 
basolateral compartment (1-2 ml·min-1) for at least 45 min. 
 In the mean time, manually purge the interface tubing between the apparatus 
and the SIA eight port valve (sampling port D, A and B) and also the connecting 
tubing to the autosampler tip as well as the flow through detector cell 
(fluorescence and/or UV).  
 UV detection: post washing the detector cell; perform a dark scan with the UV 
detector and subsequently a reference scan. 
 Post purging the apparatus, close the basolateral compartment. Add sufficient 
volume of KRB (pH 7.4) in the basolateral vessel. Then, let the SIA peristaltic 
pump run until no more air bubble are visible in the tubing. Subsequently, turn 
off the SIA peristaltic pump.  
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 In order to exclude any air bubbles in the basolateral compartment press the 
“prime drain” button at the basolateral membrane dosage pump. Do not turn off 
the pump until any more air bubble escape out of the FPTC. Assure that during 
that procedure, the basolateral vessel does not run out of KRB. 
 Add a "waste" Falcon® tube in standard tray position 10 of the autosampler. 
 Open an appropriate SIA program for the experiment. 
If analysis of the permeated compound by means of HPLC is planned, add sufficient 
HPLC vials with 200 µl inserts (CE Chromatographieservice, Langerwehe-Jüngersdorf, 
GE) into the autosampler tray (technical depiction given in Figure 8.7 and Figure 8.8).  
 
 
Figure 8.1. Allocation of the various positions on the autosampler tray. Numbers and arrow indicate the 
progression of the autosampler tip (first column sample tray 1; second column sample tray 2; ...). 
8.2.1.2 Preparing the flow dissolution apparatus 4 
 Add a ruby bead in the flow through cell 
 Add approximately 1 g of glass beads into the flow cell 
 Place the tablet onto the glass beads by means of tweezers 
 Insert a filter sheet (type GF/D, Whatman International Ltd, Maidstone, UK) in the 
head of the apparatus 4 by means of tweezers.  
 Connect the stainless steel bracket of the apparatus to the tubing of the 
dissolution pump (3 way valve). (this has to be done prior to assembling the 
apparatus 4) 
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 Turn on the dissolution pump in order to purge the “heating spiral” and the 
tubing between the apparatus 4 and the pump for 3 min with the respective 
KRB. Remove the buffer from the outlet by means of a Pasteur pipette. Then turn 
off the dissolution pump. 
 Assemble the apparatus 4 completely, place it in the water bath, and connect 
also its outlet. Confirm that the 3-way valves are set correctly. 
8.2.1.3 Preparing the Caco-2 cell monolayer 
 Fill 50 ml of each KRB buffer in Falcon® tubes (Becton-Dickinson, Heidelberg, 
GE) and preheat those to 37 °C. 
 Wash the Caco-2 cell monolayer twice with KRB. 
 Equilibrate for at least 30 min. When assessing P-gp – surfactant interaction 
equilibrate for 60 min with the respective surfactant containing buffer. 
 After the equilibration assess TEER value and microscopical appearance of the 
monolayer. 
8.2.1.4 Inserting Caco-2 cell monolayer into the FTPC 
 Prepare appropriate Falcon® tubes with preheated KRB buffer for primary filling 
of the FTPC 
 Place the Transwell® plate with the Caco-2 monolayer in front of the water bath. 
Then, take the FTPC out the water bath, open it by means of an Allen key. 
Remove all KRB in the FTPC by means of a Pasteur pipette. After filling the 
basolateral cavity of the FTPC with the KRB ph 7.4, insert the Transwell® and 
finally add the respective apical KRB solution. Subsequently, close the FTPC 
cautiously in order to prevent deleterious pressure on the Caco-2 monolayer and 
submerse the FTPC in the water bath. 
 Turn on all pumps (dissolution, apical and basolateral) except the SIA peristaltic 
pump. Assure that the basolateral vessel is not running out of KRB. Turn on the 
apical and basolateral pump simultaneously. 
 Let the pumps run until basolaterally and apically no air bubbles are escaping 
the FTPC, but a least for 10 min. Then, turn off all pumps. 
 In order to warrant a reproducible volume of KRB in the basolateral 
compartment, empty the basolateral vessel by means of a Pasteur pipette 
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completely. Subsequently, add 1.0 ml of KRB pH 7.4 into the vessel. Close the 
basolateral vessel by means of an Allen key. 
 
8.2.1.5 Starting the analysis. 
 
 Be sure, that all tubes are connected tightly and that all SIA devices are logged 
on.  
 Control all three way valves for their correct position. 
 Be sure that the buffer bottle prior to the dissolution pump is submersed in the 
water bath and is weighted down by means of a lead donut. (Otherwise, the 
bottle might afloat in the water bath when the water level in the bottle falls 
throughout the experiment) 
 To start the real experiment, simultaneously turn on the dissolution pump and 
execute the SIA program. All other manually controlled pumps remain switched 
of. 
 Observe the outlet of the flow through dissolution apparatus 4. After 
approximately 2 min (depending on the flow rate of the dissolution pump and the 
internal volume of the USP apparatus 4), the air will be completely driven out of 
the flow through dissolution cell and KRB will again fill the tubing. 
 When KRB reaches the stream splitter, wait for another 2 seconds and 
subsequently turn on all other manually controlled pumps. 
 Wait for the first sample aspirated and injected into the flow through absorption 
device. Be sure, that no air bubbles were allowed to enter the flow through 
absorption device. Check in the analysis window of the SIA software the shape 
and baseline of the first peak. If this peak is OK, check for another time all other 
devices for their proper function and all fill levels.  
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8.3 Programming codes for SIA for analysis of propranolol HCl in KRB 
 
8.3.1 Main routine for propranolol HCl 
 
Peristaltic Pump Clockwise(%) 20 
Peristaltic Pump On 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 50\Probenzug basolateral 1.fia 
 
 
Delay (sec) 30 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 50\Probenzug basolateral 1.fia 
 
        Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
 
Loop Start (#) 20 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug dissolution 25- neuer 
Propenzug.fia 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 25\Probenzug apical 25- neuer Probenzug.fia 
 
 
       Insert File C:\Programme\WINFIA 5.0\Programm September 2005\probenzug 50\Probenzug basolateral 1.fia 
 
 
         Delay (sec) 15 
 
 
Loop End 
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8.3.2 Aspiration and analysis of propranolol HCl at sampling port D (dissolution) 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Aspirate (microliter) 1000 
 
Multiposition Valve dissolution  
 
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done  
 
Multiposition Valve waste  
 
Syringe Pump Flowrate (microliter/sec) 200 
Syringe Pump Dispense (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve dissolution   
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
Multiposition Valve  PMT-FL   
 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty  
 
Analyte New Sample  
Analyte Name dissolution 
 
PMT Start Scans  
 
Syringe Pump Delay Until Done  
 
PMT Stop Scans  
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8.3.3 Aspiration and analysis of propranolol HCl at sampling port A (apical) 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 1000 
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Multiposition Valve apical  
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve waste  
 
Syringe Pump Flowrate (microliter/sec) 200 
Syringe Pump Dispense (microliter) 200 
Syringe Pump Delay Until Done  
 
Multiposition Valve apical  
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
 
Multiposition Valve  PMT-FL   
 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Empty  
 
Analyte New Sample  
Analyte Name apical 
 
PMT Start Scans  
 
Syringe Pump Delay Until Done  
 
PMT Stop Scans  
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8.3.4 Aspiration and analysis at of propranolol HCl sampling port B (basolateral) 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 1500 
Multiposition Valve basolateral  
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
Multiposition Valve waste  
 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Dispense (microliter) 50 
Syringe Pump Delay Until Done  
 
Multiposition Valve basolateral  
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done  
 
Multiposition Valve  PMT-FL   
 
Analyte New Sample  
Analyte Name basolateral 
 
Syringe Pump Flowrate (microliter/sec) 50 
Syringe Pump Dispense (microliter) 1000 
 
PMT Start Scans  
 
Syringe Pump Delay Until Done  
 
PMT Stop Scans  
 
Multiposition Valve replenishing  
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve basolateral  
 
Syringe Pump Dispense (microliter) 75 
Syringe Pump Delay Until Done  
 
 
Multiposition Valve waste  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Empty  
Syringe Pump Delay Until Done  
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8.4 Programming codes for SIA for analysis of furosemide in KRB 
 
8.4.1 Main routine for furosemide 
 
Hardware Settings Wavelength 1 (nm) 275 
Hardware Settings Wavelength 2 (nm) 276 
Hardware Settings Wavelength 3 (nm) 344 
Hardware Settings Wavelength 4 (nm) 360 
 
 
Spectrometer Reference Scan  
 
Variable Define New sampos 
 
sampos = 1 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\basolateral-offen 
Kompartiment.fia 
 
Delay (sec) 55 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\apical.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\apical.fia 
 
sampos += 1 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\basolateral-offen 
Kompartiment.fia 
 
Loop Start (#) 40 
 
sampos += 1 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\apical.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\apical.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\dissolution.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\apical.fia 
 
Insert File C:\Programme\WINFIA 5.0\Furosemid dissolution measurement\Subroutinen DisPer measurement\basolateral-offen 
Kompartiment.fia 
 
Loop End  
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8.4.2 Aspiration and analysis of furosemide at sampling port D (dissolution) 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 750 
Multiposition Valve  dissolution   
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Syringe Pump Flowrate (microliter/sec) 100 
Syringe Pump Aspirate (microliter) 50 
Syringe Pump Delay Until Done  
 
Multiposition Valve  Waste    
 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Dispense (microliter) 300 
Syringe Pump Delay Until Done  
 
Multiposition Valve  dissolution   
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done 
 
Delay (sec) 2 
 
Multiposition Valve  UV- detector 
 
Syringe Pump Flowrate (microliter/sec) 30 
 
Analyte New Sample  
Analyte Name Dis 
 
Spectrometer Absorbance Scanning  
 
Delay (sec) 3 
  Syringe Pump Empty  
  Syringe Pump Delay Until Done  
 
Spectrometer Stop Scanning  
 
__________________________________________________________________________________________ 
Annexes 
8-117 
8.4.3 Aspiration and analysis of furosemide at sampling port A (apical) 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 750 
Multiposition Valve  apical    
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve  Waste   
 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Dispense (microliter) 350 
Syringe Pump Delay Until Done  
 
Multiposition Valve  apical    
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done 
 
Delay (sec) 2 
  
Multiposition Valve  UV- detector   
 
Syringe Pump Flowrate (microliter/sec) 30 
 
Analyte New Sample  
Analyte Name Api 
 
Spectrometer Absorbance Scanning  
 
Delay (sec) 3 
Syringe Pump Empty  
Syringe Pump Delay Until Done  
 
Spectrometer Stop Scanning  
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8.4.4 Aspiration and analysis of furosemide at sampling port B (basolateral) 
 
 
 
 
 
 
Syringe Pump Valve In  
 
Syringe Pump Flowrate (microliter/sec) 500 
Syringe Pump Aspirate (microliter) 750 
Multiposition Valve  basolateral 
Syringe Pump Delay Until Done  
 
Syringe Pump Valve Out  
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
Syringe Pump Delay Until Done  
 
Multiposition Valve  Waste   
 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Dispense (microliter) 350 
Syringe Pump Delay Until Done  
 
Multiposition Valve  PMT-FL   
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
Multiposition Valve  basolateral    
 
Syringe Pump Flowrate (microliter/sec) 15 
Syringe Pump Aspirate (microliter) 100 
 
autosampler Wash  
autosampler standard rack (sample #) 10 
 
Syringe Pump Delay Until Done  
 
Multiposition Valve  PMT-FL   
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Aspirate (microliter) 25 
Syringe Pump Delay Until Done  
 
Multiposition Valve  autosampler   
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Dispense (microliter) 210 
Syringe Pump Delay Until Done  
 
autosampler RACK 2 (sample #) sampos 
 
Delay (sec) 0,2 
 
Syringe Pump Flowrate (microliter/sec) 25 
Syringe Pump Dispense (microliter) 110 
Syringe Pump Delay Until Done  
 
autosampler standard rack (sample #) 10 
 
Syringe Pump Flowrate (microliter/sec) 250 
Syringe Pump Dispense (microliter) 350 
Syringe Pump Delay Until Done  
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8.4.5 Configuration of the autosampler rack 
8.4.5.1 Configuration of the autosampler rack for the 10 standard falcon tubes  
 
name of rack : standard rack 
number of rows: 5 
number of columns: 2 
X position of Sample #1 [mm]: 1 
Y position of Sample #1 [mm]: 53 
Delta X position of samples in rack [mm]: 30 
Delta Y position of samples in rack [mm]: 36 
Up position [mm]: 50 
Down position [mm]: 70 
 
Table 8.1. Standard tray autosampler configuration 
 
8.4.5.2 Configuration of the autosampler rack for HPLC vial filling  
 
name of rack : standard rack 
number of rows: 5 
number of columns: 2 
X position of Sample #1 [mm]: 1 
Y position of Sample #1 [mm]: 53 
Delta X position of samples in rack [mm]: 30 
Delta Y position of samples in rack [mm]: 36 
Up position [mm]: 50 
Down position [mm]: 70 
 
Table 8.2. HPLC vials tray autosampler configuration 
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8.4.6 Configuration of the UV spectrometer (USB 2000) 
 
parameter setting 
integration time [ms] : 80 
detectors to average : 1 
samples to average : 3 
sample rate [Hz] : 4 
plotting threshold [counts] : 0 
offset absorbance : 0 
scale voltage : 10 
  
first coefficient : 0.3832872 
second coefficient : -1.45952 ·10-5 
third coefficient : -2.31592·10-9 
intercept : 177.4774 
 
Table 8.3. Setting of the spectrometer for furosemide UV - SIA analysis. 
 
 
 
8.4.7 Port allocation of the multiposition valve for propranolol HCl 
 
allocation port position 
waste 1 
autosampler 2 
KRB for replenishing 3 
basolateral 4 
apical 5 
dissolution 6 
-- 7 
PMT-Fl 8 
 
Table 8.4. SIA port allocation for propranolol HCl. 
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8.4.8 Port allocation of the multiposition valve for furosemide 
 
allocation port position 
waste 1 
autosampler 2 
-- 3 
basolateral 4 
apical 5 
dissolution 6 
"air" 7 
UV detector 8 
 
Table 8.5. SIA port allocation for furosemide. 
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8.5 Engineering detail drawings 
 
In the following, the gauges of the custom made parts of the apparatus for permeability 
assessment of solid oral dosage formulations based on a Caco-2 monolayer and a flow 
through dissolution cell are given. Gauges are given where necessary in millimetre. 
 
 
8.5.1 Technical depiction of the stream splitter 
 
 
 
 
Figure 8.2. Stream splitter, material PEEK 
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8.5.2 Technical depiction of the FTPC 
 
 
 
Figure 8.3. Middle part of the FTPC, material PEEK 
 
 
 
 
Figure 8.4. Apical part of the FTPC, material PEEK 
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Figure 8.5. Basolateral part of the FTPC, material PEEK 
 
8.5.3 Technical depiction of the basolateral vessel 
 
 
Figure 8.6. Basolateral vessel, material PEEK. 
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8.5.4 Technical depiction of the autosampler tray 
 
 
Figure 8.7. Top view on the autosampler tray, material POM 
 
 
 
 
Figure 8.8. Lateral view on the autosampler tray, material POM 
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